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Abstract 
 
Melanoma remains the most aggressive and fatal type of skin cancer. In greater 
than 50% of cases, patients present with an activating BRAF mutation (BRAF+), leading 
to upregulated mitogen-activated protein kinase (MAPK) pathway signaling. Of these 
patients, 80-90% have a missense mutation at codon 600 (e.g., BRAFV600E), making the 
mutant form of the protein an attractive and druggable target. In 2011, the FDA approved 
combination therapy of BRAF+ and MEK inhibitors (BRAFi/MEKi), like vemurafenib and 
cobimetinib (Ve/Cb), for use in unresectable late-stage melanoma patients, drastically 
changing treatment options and initial outcomes. Still, the majority of patients become 
refractory to BRAFi/MEKi within the first year of treatment. The lack of treatment durability 
underscores the need for novel therapeutic strategies and drug candidate development, 
such as the utilization of molecular chaperone inhibitors. 
The 90-kDa heat shock protein (Hsp90) is a molecular chaperone and responsible 
for stabilizing the protein folding of “client” proteins that interact with the heterochaperone 
complex that Hsp90 forms with the 70-kDa heat shock protein (Hsp70) and other co-
chaperones. These clients are involved in several cellular signaling pathways and 
processes, highlighting the significance of chaperone function in eukaryotic cells. 
Interestingly, Hsp90 expression increases several-fold in cancer cells to compensate for 
cellular stress and client protein dependence on chaperone function. To-date 18 small 
molecule Hsp90 inhibitors (Hsp90i) entered clinical trials, of which 94.4% target the N-
terminus (NT-Hsp90i) but failed to get FDA approval. The NT-Hsp90i are effective and 
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potent, but pan-inhibitors of all four Hsp90 isoforms. In clinical trials, patients require 
dose-escalation of NT-Hsp90i to reach a therapeutic effect, ultimately leading to dose-
limiting toxicities (DTL). Studies suggest a link between DTLs and the activation of the 
heat shock response (HSR), especially the cytoprotective role of Hsp70. Previously, our 
lab, with collaborators, developed novel C-terminal Hsp90i (CT-Hsp90i) and showed 
efficacy in several cancer models in vitro and in vivo while mitigating the HSR, suggesting 
a decreased toxicity profile compared to NT-Hsp90i.  
For this dissertation, I researched therapeutic resistance mechanisms in BRAF+ 
melanoma through various preclinical in vitro studies that targeted Hsp90. Specifically, I 
tested the hypothesis that several resistance-promoting processes require Hsp90 
function and, therefore, could be targeted with an Hsp90i to simultaneously knockdown 
resistance pathways and oncogenic processes. First, I showed effective melanoma cell 
death using the CT-Hsp90i KU758 at potent micromolar concentrations (e.g., IC50 = 
0.36µM – 0.43µM). Next, I demonstrated robust synergy (e.g., CI<0.5) of KU758 when 
combined with either a BRAFi or MEKi to target two resistance pathways effectively (e.g., 
MAPK/Erk and PI3K/Akt), significantly mitigate melanocyte migration, and downregulate 
key Hsps involved in HSR activation. Finally, I accessed publicly available genomic data 
via the National Cancer Institute and The Cancer Genome Atlas (TCGA) program to 
identify additional genes of interest in BRAF+ melanomas. Using a clustered heatmap of 
RNA expression data, I distinguished genes of interest based on common expression 
alterations amongst a subset of BRAF+ melanoma patients to provide a genetic 
perspective in the context of Hsp90i use in melanoma patients. 
Collectively, this work reviews the use of and development of several small 
  xvii 
molecule inhibitors in melanomas (e.g., BRAFi/MEKi and Hsp90i), identifies a novel and 
effective KU758-combination approach in BRAF+ melanomas, and gives insight into 
future therapeutic directions based on various translational and genetic signatures in 
these difficult-to-treat tumors.   
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Chapter 1   
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers1 
 
Abstract 
The mitogen activated protein kinase/extracellular signal-related kinase 
(MAPK/ERK) signaling pathway serves an integral role in growth, proliferation, 
differentiation, migration, and survival of all mammalian cells. Aberrant signaling of this 
pathway is often observed in several types of hematologic and solid malignancies. The 
most frequent insult to this signaling cascade, leading to its constitutive activation, is to 
the serine/threonine kinase rapidly accelerating fibrosarcoma (RAF). Considering this, the 
development and approval of various small molecule inhibitors targeting the MAPK/ERK 
pathway has become a mainstay of treatment as either mono- or combination therapy in 
these cancers. Although effective initially, a major clinical barrier with these inhibitors is 
the relapse of patients due to drug resistance. Knowledge of the mechanisms of 
resistance to these drugs is still premature, highlighting the need for a more in-depth 
understanding of how patients become insensitive to these pharmacologic interventions. 
Herein, we will succinctly summarize the milestones in the approval of select MAPK/ERK 
pathway inhibitors, their use in patients, and major modes of resistance. 
  
 
1 This chapter was published in Drugs (PMID: 29488071) and completed in collaboration with the 
following authors: Ton Wang and Mark S. Cohen. 
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Introduction 
The MAPK/ERK signaling pathway is evolutionarily conserved and critical in 
regulating cell growth, proliferation, differentiation, migration, and survival [1]. 
Unfortunately, in many cancers including melanoma, thyroid, colorectal, non-small cell 
lung cancer (NSCLC), and hairy cell leukemia (HCL) this signaling pathway is altered 
leading to uncontrolled cellular processes, constitutive activation and cancer cell growth. 
Given the strong link of aberrations in this pathway and cancer cell growth, targeted 
inhibition of this pathway has become a central focus of cancer therapeutic development 
in recent years [2]. This effort has led to the development and Food and Drug 
Administration (FDA) approval of several small molecule inhibitors targeting mitogen-
activated protein kinase/extracellular-signal regulated kinase (MAPK/ERK) pathway 
tyrosine kinase proteins such as BRAF and MEK [3,4]. The MAPK/ERK pathway is 
activated by extracellular signaling molecule(s) that bind to their respective trans- 
membrane receptor tyrosine kinases (RTKs), such as epidermal growth factor (EGF) and 
its receptor (EGFR), respectively. Upon receptor activation, the extracellular signal is 
transduced inside the cell, subsequently activating the GTPase, rat sarcoma protein 
(RAS), via guanine nucleotide exchange from guanosine diphosphate (GDP) to 
guanosine triphosphate (GTP). The active GTP-bound- RAS can then initiate activation 
of the three-tier MAPK cascade – RAF  MEK  ERK (RAF, rapidly accelerated 
fibrosarcoma; MEK, mitogen activated protein kinase). As the final protein kinase in the 
pathway, activated ERK is then able to phosphorylate downstream cytoplasmic and/or 
nuclear effectors that regulate and ultimately alter cell growth, proliferation, differentiation, 
migration, and survival [1-3]. 
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As mentioned previously, the MAPK/ERK pathway is frequently altered at its early 
stages. This includes overexpression/amplification of RTKs, activating mutations to 
RTKs, sustained production of signaling molecules, and point mutations of RAS or RAF. 
Although the MAPK/ERK signaling pathway can be altered at various places, many 
cancers present with mutations to RAF [5,6]. In melanoma, more than 50% of patients 
present with a point mutation to the BRAF isoform at codon 600, where a valine is 
substituted for glutamate (V600E) in almost 90% of cases [7]. A recent genomic analysis 
of melanomas through next-generation sequencing and the cancer genome atlas project 
demonstrated that BRAF hot-spot mutations are the most common mutation identified, 
with 52% harboring BRAF somatic mutations; the most common being V600E (75%), 
followed by V600K (11%), K601 (3%), and V600R (2%). Both BRAF V600 and K601 hot-
spot mutations were anti-correlated with hot-spot NRAS mutations while BRAF non-hot-
spot mutations co-occurred with RAS (N/H/K) hot-spot and NF1 mutations [8]. Similar to 
melanoma, approximately 45% of papillary thyroid cancers and 10% of colorectal cancer 
patients harbor similar BRAF mutations [9-11]. Interestingly, this same mutation has been 
found in 100% of HCL patients [12]. It has become apparent in the last few years that a 
large subset of patients with these cancers are affected by aberrations to the MAPK/ERK 
pathway, specifically BRAF, which has led to the development and approval of small 
molecule BRAF inhibitors for the treatment of these malignancies. While BRAF has been 
shown as an effective target in the MAPK/ERK pathway for several cancers where this 
pathway is aberrant, other selective small molecule inhibitors of MEK, the downstream 
effector of RAF, have also been recently developed and are now FDA approved for use 
in cancer patients [13]. Despite their initial efficacy, however, the biggest barrier faced in 
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the clinic with these selective small molecule inhibitors is the emergence of resistance 
following treatment in a majority of patients. This resistance can come from a myriad of 
escape mechanisms that cancer cells have developed to overcome this targeted drug 
effect. Given the multiple mechanisms of resistance that exist with these inhibitors, 
overcoming this resistance does not have a simple solution and is the ongoing work of 
many researchers and clinicians. 
In this review, we will discuss landmark clinical trials investigating the use of 
MAPK/ERK pathway inhibitors as monotherapy and in combination for the treatment of 
melanoma, thyroid cancer, colorectal cancer, NSCLC, and HCL. Further discussion will 
also describe a detailed overview of the mechanisms of resistance to these inhibitors and 
the current clinical application of these inhibitors including their application in standard-
of-care treatment regimens, costs, and side effects. 
 
MAPK/ERK Pathway Inhibitors as Monotherapies 
BRAF Inhibitors 
Vemurafenib 
Vemurafenib (formerly PLX4032; brand name Zelboraf; developed by Plexxikon 
and Genentech) was approved by the FDA in 2011 and by the European Commission in 
2012 for the treatment of BRAFV600E-mutated late-stage melanoma. This reversible, small 
molecule inhibitor is orally administered and causes apoptosis of melanoma cells by 
selectively targeting BRAFV600E mutations.  
In 2009, a Phase I multicenter study was conducted in patients with metastatic 
cancer to identify the maximum tolerated dose and safety and pharmacokinetic profiles 
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of the selective BRAF inhibitor [14]. Of the 55 patients enrolled in the dose-escalation 
study, 49 patients had metastatic melanoma and 16 patients in this subset harbored the 
BRAFV600E mutation. Newly enrolled patients were administered PLX4032 at 160 mg 
twice daily followed by escalation. During the study, dose-limiting toxicities were first 
observed at 720 mg twice daily of PLX4032 with minor adverse effects (AEs) such as 
grade 2 or 3 rash, fatigue, and arthralgia. These AEs were also observed in patients given 
doses up to 1120 mg twice daily. Of the 16 patients with BRAFV600E mutant melanomas, 
partial and complete responses were seen in 11 patients (10 and 1, respectively). 
Following the dose-escalation phase of the study, an extension phase was completed in 
an additional 32 patients with BRAFV600E-mutated metastatic melanoma. Patients were 
administered 960 mg twice daily and showed partial and complete responses in 24 and 
2 patients, respectively. From this, the recommended Phase II dose (RP2D) was 
established as 960 mg twice daily. Overall, this study demonstrated that the use of 
vemurafenib as a targeted therapy in humans with metastatic melanoma harboring the 
activating BRAFV600E mutant is safe. Additionally, dosing for further clinical trials was 
determined. 
In 2011, the Phase II clinical trial (BRIM-2) conducted by Ribas and colleagues 
was pivotal in showing the efficacy of vemurafenib in previously treated metastatic 
melanoma patients with the BRAFV600E mutation [15]. The primary endpoint of this open-
label, multicenter study was overall response rate (ORR) to vemurafenib in stage IV 
melanoma patients who had previously received either one or more systemic therapies. 
Secondary endpoints included the duration of patient response to vemurafenib, 
progression-free survival (PFS), overall survival (OS), and safety. In BRIM-2, 53% of 
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patients demonstrated response overall, and the median duration of response was 6.8 
months. The AEs observed in the study were similar to the Phase I trial of PLX4032, 
which included rash, fatigue, and arthralgia. In addition, investigators noted liver function 
abnormalities and the development of secondary skin tumors. These skin lesions were 
the most common Grade 3 AEs and are thought to be the result of paradoxical 
MAPK/ERK pathway activation [16]. Cells that harbor oncogenic RAS or upregulated 
RTKs are able to evade BRAF inhibition through feedback activation of the pathway 
[17,18]. In vemurafenib-treated patients, it is suggested that oncogenic RAS has a major 
role in bypassing direct pathway inhibition [17,18]. In these cells, despite BRAF inhibition, 
cell proliferation and growth are achieved through upstream activation by RAS. Most AEs 
were manageable and could be reversed with a simple dose reduction. Results from the 
BRIM-2 study, including the ORR of 53%, demonstrated the effectiveness of vemurafenib 
in BRAFV600E melanoma patients previously treated with other systemic agents. 
Following these early Phase I and II clinical trials, a randomized Phase III clinical 
trial was performed directly comparing the efficacy of vemurafenib to dacarbazine in 
previously untreated metastatic melanoma patients with the BRAFV600E mutation [19]. The 
co-primary endpoints of the study were OS and PFS, whereas secondary endpoints were 
response rate, duration, and safety. In this trial, 675 patients were randomly assigned to 
receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per 
square meter of body surface area intravenously every 3 weeks). After 6 months of 
treatment, the OS was found to be higher in vemurafenib treated patients (84%) com- 
pared to dacarbazine treated patients (64%). Due to the significant benefit observed in 
the vemurafenib group, crossover from dacarbazine to vemurafenib was recommended 
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in patients not responding to dacarbazine. Common minor AEs to vemurafenib again 
included rash, fatigue, arthralgia, alopecia, photosensitivity, and nausea, and were 
typically managed with dose reduction. Eighteen percent of patients treated with 
vemurafenib developed secondary skin tumors, which were treated with simple excision. 
In addition to the increased OS, vemurafenib also improved median PFS in previously 
untreated BRAFV600E metastatic melanoma patients to 5.3 months versus 1.6 months in 
dacarbazine-treated patients. 
Vemurafenib is FDA approved (August 2011) for use in unresectable metastatic 
melanoma harboring the BRAFV600E mutation, but on-going clinical trials are now testing 
this selective, small inhibitor in other cancer models, specifically those with the same 
activating BRAF mutation (V600E or V600K), such as thyroid cancer and HCL. In an 
ongoing pilot study, the efficacy of vemurafenib used alone or in combination with 
radioiodine in radioiodine refractory BRAF mutant thyroid cancers (ClinicalTrials.gov 
Identifier: NCT02145143) is being tested to determine treatment effects. Similarly, there 
are on-going clinical trials testing the efficacy of vemurafenib in HCL. Notably, there is 
one completed multicenter Phase II trial that reports >96% response rates in patients and 
a median of 23 months for response duration [20]. In 2017, the FDA approved 
vemurafenib in the treatment of Erdheim Chester Disease. As a whole, these studies 
show promising results for the possibility of vemurafenib approval in other cancers 
harboring activating BRAF mutations.  
The approval for use of vemurafenib in metastatic melanoma has changed the 
current standard of care and patient prognosis. Both preclinical and clinical studies have 
shown the efficacy of selectively targeting a protein that plays a major role in a pathway 
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contributing to tumor progression. Although vemurafenib has dramatically altered the 
breadth of treatment options for patients, it is important to highlight that vemurafenib is 
rarely used as monotherapy and is instead more efficacious in combination therapy with 
MEK inhibitors. This is in large part due to the feedback activation of the MAPK/ERK 
pathway observed with single-agent treatment with vemurafenib. Combination strategies 
and why they are more effective than the use of vemurafenib alone will be discussed in a 
later section. 
Dabrafenib 
Dabrafenib (formerly GSK2118438; brand name Tafinlar; developed by 
GlaxoSmithKline) was approved by the FDA and the European Union for use in 
unresectable or metastatic BRAFV600E or BRAFV600K melanoma in 2013. Like 
vemurafenib, dabrafenib is a reversible, small molecule inhibitor of the kinase BRAF 
harboring the V600E or V600K mutation. The use of dabrafenib is contraindicated in 
patients with wild-type BRAF (BRAFWT) due to the risk of tumor progression in these 
patients. Melanoma patients with BRAFWT have a unique response to selective BRAF 
inhibitors by demonstrating hyperactivation of the MAPK/ERK pathway. Although the 
exact mechanism has yet to be elucidated, there is evidence to suggest that selective 
BRAF inhibitors drive the dimerization of other RAF isoforms, like CRAF [21,22]. 
Alternatively, Holderfield and colleagues proposed a mechanism that interrupts inhibitory 
autophosphorylation of the protein [23]. This allows for paradoxical pathway activation 
independent of BRAF ultimately leading to cell proliferation. 
During the initial Phase I study from 2009 to 2012, the tolerability and safety of 
dabrafenib was tested at multiple centers in Australia and the U.S.A. to ultimately 
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establish a standard recommended dose to be used in Phase II trials [24]. In this study, 
patients with the BRAFV600E mutation were treated with dabrafenib in a dose-escalation 
protocol. Dabrafenib was well-tolerated in patients with an activating BRAFV600E mutation, 
with most AEs as minor and these included fatigue, pyrexia, and cutaneous squamous 
cell carcinoma (SCC). Although dabrafenib administration was increased to 300 mg twice 
daily in this study, no maximum tolerated recorded dose was noted and 150 mg twice 
daily was established as the RP2D. 
The clinical efficacy and safety of dabrafenib was tested in a multicenter Phase II 
(BREAK-2) trial in patients with metastatic BRAF-mutated melanoma [25]. Patients 
enrolled in the study received dabrafenib 150 mg twice daily orally until they experienced 
dose-limiting AEs, disease progression, or death. The primary endpoint of the BREAK-2 
study was ORR, while PFS and OS were secondary endpoints. The study enrolled 
patients with BRAFV600E (76 patients) and BRAFV600K mutations (16 patients) with a 
confirmed response rate of 59 and 13%, respectively. Results from the trial supported 
that dabrafenib was an active agent in both BRAFV600E and BRAFV600K mutations, but 
more effective in patients with the V600E mutation. The median PFS was 6.8 months in 
BRAFV600E patients and 4.5 months in BRAFV600K patients. The most common AEs 
observed during the Phase II study were arthralgia, pyrexia, and hyperkeratosis; 10% of 
patients developed secondary skin tumors. Overall, BREAK-2 confirmed the safety and 
activity of dabrafenib in metastatic melanoma patients with BRAFV600E mutations. 
FDA approval of dabrafenib in 2013 for unresectable or metastatic melanoma was 
based on results from a multicenter international, open label randomized, active control 
Phase III trial [26]. In this study, the improvement in PFS was observed in patients treated 
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with dabrafenib compared to systemic treatment with dacarbazine. In this study, 250 
patients with previously untreated disease and BRAFV600E mutations were enrolled. The 
median PFS of dabrafenib-treated    patients    was    5.1 months    compared    to only 
2.7 months with dacarbazine; patients from the dacarbazine treatment group were 
allowed to cross over to the dabrafenib treatment group. The AEs of dabrafenib in this 
study were similar to those observed in earlier Phase I and II trials, but also included 
erythrodysesthesia palmar plantar syndrome and papilloma. At the end of this study, 
dabrafenib was recommended for use in BRAFV600E-positive unresectable or metastatic 
melanoma at a dose of 150 mg twice daily. Ongoing clinical efficacy trials of dabrafenib 
are currently enrolling in both papillary thyroid cancer (ClinicalTrials.gov Identifier: 
NCT01723202) and refractory leukemia (ClinicalTrials.gov Identifier: NCT03091257; 
NCT02551718). 
Similar to vemurafenib, dabrafenib has improved treatment options for patients but 
has been shown to be most effective when used in combination with other therapies that 
target the MAPK/ERK pathway or immune response. These combinations will be 
discussed in the following section. 
Encorafenib 
Encorafenib (also known as LGX818; developed by Novartis), is a selective 
BRAFV600E inhibitor currently in Phase III trials to be approved for use in combination with 
a MEK inhibitor in BRAF-mutated melanoma. Despite sharing the same selectivity for 
mutant BRAF with the inhibitors mentioned in previous sections, encorafenib has some 
unique characteristics that distinguish it from other BRAF inhibitors, providing potential 
therapeutic benefit. In September 2017, Deloard and colleagues published preclinical and 
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clinical (Phase I) data on the potent small molecule inhibitor [27]. The preclinical data 
show that encorafenib is not only more potent than its counterparts (vemurafenib and 
dabrafenib), but also has a longer dissociation half-life. Moreover, encorafenib treatment 
results in less severe AEs than observed in vemurafenib- and dabrafenib-treated patients, 
including secondary skin tumors. The finding that encorafenib is more potent, has a longer 
dissociation half-life, and a lower incidence of secondary skin tumors makes it a promising 
drug in the pipeline for approval. In the Phase I clinical trial, the primary objective was to 
determine the maximum tolerated dose (MTD) and RP2D. BRAF inhibitor-naive and 
previously treated patients were enrolled in the study, where the former group of patients 
responded better. The ORR in BRAF inhibitor-naive patients was 60% and minimal in 
patients previously treated with a BRAF inhibitor. The MTD was determined to be 450 mg 
twice daily, but due to dose-limiting toxicities in the extension phase of the study the PR2D 
was declared as 300 mg twice daily. During Phase I of the trial, the standard of care for 
the metastatic melanoma shifted greatly to the use of BRAF and MEK inhibitors in 
combination. As a result, encorafenib clinical trials progressed forward to test its use in 
combination with the MEK inhibitor binimetinib. This combination treatment strategy will 
be discussed in subsequent sections. 
Sorafenib 
Sorafenib (brand name Nexavar; co-developed by Bayer and Onyx 
Pharmaceuticals), is a multi-targeted tyrosine kinase inhibitor (TKI) that is FDA and 
European Union  approved for use in renal cell carcinoma (RCC), hepatocellular 
carcinoma (HCC), and radioactive-iodine refractive differentiated thyroid cancer (RAIR 
DTC) [28,29].  Although originally discovered as a Raf-1 inhibitor, sorafenib has since 
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been found to be a potent inhibitor of several other kinases including BRAF. In 2005 and 
2007, the FDA approved the use of sorafenib in RCC and HCC, respectively. Its indication 
in RCC was based on the Phase III clinical trial, TARGET (Treatment Approaches in 
Renal Cancer Global Evaluation Trial), which determined the effect of sorafenib or 
placebo on OS and PFS in patients with advanced RCC [30]. In this study, the median 
OS was 19.3 and 15.9 months and PFS was 5.5 and 2.8 months in sorafenib- and 
placebo-treated groups, respectively. Sorafenib’s approval for use in HCC was based on 
the Phase III clinical trial, SHARP (Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol), which compared the administration of sorafenib or placebo in 
previously untreated patients with unresectable disease [31]. In this international 
multicenter study, OS and time to symptomatic progression were the primary endpoints. 
Pharmacological intervention showed a significant increase in median OS from 7.9 
months in placebo-versus 10.7 months in sorafenib-treated patients. There was no 
significant difference observed in time to symptomatic progression. 
The 2013 FDA approval of sorafenib in RAIR DTC was based on the Phase III 
randomized control trial, DECISION [32]. In this study, 417 patients with RAIR DTC were 
randomized to undergo treatment with sorafenib or placebo; patients treated with 
sorafenib demonstrated median PFS of 10.8 versus 5.8 months with placebo [hazard ratio 
(HR) was 0.59; 95% CI, 0.45–0.76;  p\0.0001], with a 41% decrease in risk of disease 
progression or death. There are numerous on-going clinical trials testing sorafenib in solid 
and hematological tumors including breast cancer, glioma, and acute myeloid leukemia. 
In these trials, the efficacy of sorafenib is being tested alone or in combination with the 
current standard of care, whether it be chemotherapy or targeted therapy, in each 
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respective malignancy. In addition to these on-going trials, there is work in chronic 
myelomonocytic leukemia (CMML) using sorafenib (ClinicalTrials.gov; Identifier: 
NCT01620216). In 2014, Zhang and colleagues showed that a subset of CMML patients 
with wild-type RAS harbor mutations in its downstream effector, BRAF [33]. This gives 
premise for the use of targeting BRAF in CMML since it is mutated and contributes 
towards pathway activation and subsequent tumor progression. Taken together, future 
work is warranted evaluating the use of selective BRAF inhibitors. 
MEK Inhibitors 
Trametinib 
Trametinib (brand name Mekinist, GlaxoSmithKline Pharmaceuticals) was 
approved by the FDA in 2013 and by the European Union in 2014 for unresectable or 
metastatic melanoma with BRAF (V600E or V600K) mutations. Trametinib is an orally 
administered, reversible selective allosteric inhibitor of MEK1 and MEK2 [34]. MEK is a 
kinase downstream of both RAS and RAF in the MAPK pathway. Although approved for 
monotherapy, more recent treatment strategies recommend combining trametinib with 
dabrafenib for improved effect. 
Initial Phase I studies, conducted from 2008-2010, recommended an oral dose of 
2 mg daily for trametinib, which was well-tolerated in patients with minor AEs observed 
[34]. FDA approval was ultimately based on a multicenter Phase III trial of over 300 
patients enrolled from 2010–2011 [35]. In this trial, patients were randomized to receive 
either 2 mg daily of oral trametinib or standard intravenous chemotherapy with 
dacarbazine or paclitaxel. The results of the trial showed a disease PFS of 4.8 months in 
  14 
patients receiving trametinib versus only 1.5 months in patients receiving standard 
chemotherapy and a 56% risk reduction in mortality [35]. 
Notably, a 2012 Phase II study was conducted to determine whether there is a role 
for trametinib in patients with metastatic BRAF-mutated melanoma who have previously 
been treated with a BRAF inhibitor based on the hypothesis that inhibition of MEK, which 
is downstream from BRAF, may be a useful adjunct in patients who have developed 
resistance to BRAF inhibition [36]. In this study, patients were divided into two cohorts, 
those previously treated with a BRAF inhibitor (either dabrafenib or vemurafenib) and 
those previously treated with other systemic chemo- or immunotherapy. In the group of 
patients previously treated with a BRAF inhibitor, there was a significant decrease in 
disease response; no patients showed an objective response versus 25% of patients who 
were naive to BRAF inhibitor therapy who demonstrated either complete or partial 
responses. There was a median PFS period of only 1.8 months compared to 4.0 months 
in patients who had not previously been treated with a BRAF inhibitor. This study 
suggested that the mechanisms of resistance from BRAF inhibitor treatment confer 
similar resistance to treatment with MEK inhibitors. 
In comparing trametinib with vemurafenib, a major finding of multiple studies has 
been the lack of development of cutaneous SCC with treatment of trametinib [35]. While 
dermatological side effects such as rashes are common in patients treated with both 
trametinib and vemurafenib, trametinib appears to avoid the concerning development of 
SCC found in up to one-quarter of patients who receive vemurafenib [37]. 
While currently only approved for treatment in patients with metastatic BRAFV600E- 
or BRAFV600K-mutated melanoma, there are some studies that suggest that trametinib 
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may have a role in the treatment of patients with rarer BRAF-mutations. Currently a Phase 
II study is in progress to determine the efficacy of trametinib in patients with non-
BRAFV600E mutations (ClinicalTrials.gov; Identifier: NCT02296112). 
The possible role of trametinib in the treatment of KRAS-mutated NSCLC 
treatment was investigated in a 2015 Phase II study, which enrolled 129 patients and 
randomized them to receive treatment with either trametinib or docetaxel [38]. The study 
was terminated early due to failure to demonstrate any difference in PFS between the 
groups. 
Cobimetinib 
Cobimetinib (GDC-0973 or brand-name Cotellic, developed by Exelixis and 
Genentech) was first introduced as a novel MEK inhibitor in 2012. In vitro studies 
indicated that this drug was particularly potent in BRAF or KRAS mutant cancer cell lines, 
a finding that was confirmed with in vivo human mutant xenograft tumor models [39]. In 
2014, a Phase Ib study was performed evaluating cobimetinib in conjunction with 
vemurafenib in patients with BRAF-mutated melanoma. The 129 patients who were 
enrolled in the trial had either progressed on vemurafenib or had never been trialed on a 
BRAF inhibitor. The study was able to achieve its primary endpoint of demonstrating that 
cobimetinib was safe for use in conjunction with vemurafenib. Additionally, 15% of 
patients who had previously progressed on vemurafenib prior to being enrolled in the 
study and 87% of patients who had never been trialed on a BRAF-inhibitor demonstrated 
objective responses to therapy [40]. Based on promising trial results, in 2015 the FDA 
and the European Union approved cobimetinib in conjunction with vemurafenib for the 
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treatment of advanced stage BRAFV600E or BRAFV600K-mutated melanoma. Cobimetinib 
is not approved for single-drug use [41]. 
Selumetinib 
Selumetinib (study name AZD6244, ARRY-142886) was granted orphan drug 
status by the FDA in May 2016 for the treatment of patients with stage III or IV 
differentiated thyroid cancer. Similar to trametinib, selumetinib is an orally administered 
selective, allosteric inhibitor of MEK1 and MEK2. Initial Phase I trials recommended a 
dosing of 75 mg twice daily [42]. While studied in a number of different tumors, the best-
supported application for selumetinib has been in patients with metastatic differentiated 
thyroid cancers that are refractory to radioiodine concentration. The inability of certain 
thyroid cancers to concentrate iodine has been linked to mutations in BRAF and RAS, 
both of which lead to activation of MAPK signaling [43]. A 2013 study demonstrated that 
selumetinib was able to sensitize patients with differentiated thyroid cancer who were 
previously immune to radioiodine concentration in order to allow for successful 
radioiodine treatment [44]. In this study, 20 patients with metastatic, radioiodine-resistant 
differentiated thyroid cancer were treated with selumetinib for 4 weeks. After 4 weeks of 
treatment, they underwent iodine-124 PET imaging to determine whether the tumor had 
improved iodine uptake. Of the 20 patients enrolled, selumetinib was able to increase the 
uptake of iodine in 12/20 patients [44]. The most notable response was in patients with 
NRAS mutations; 5/5 patients received radioiodine treatment with four patients 
demonstrating partial responses and one patient showing stable disease. A randomized, 
large-scale Phase III study with a goal recruitment of 400 patients is currently in progress 
to validate these results (ClinicalTrials.gov; Identifier: NCT01843062). This study, 
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expected to be completed in 2019, aims to compare the response of patients with 
differentiated thyroid cancer receiving selumetinib and radioactive iodine with those 
receiving a placebo and radioactive iodine treatment. 
Selumetinib has been studied extensively for the treatment of KRAS-mutated 
NSCLC. There have been mixed findings supporting its efficacy in this disease. A 2010 
Phase II study comparing selumetinib to standard-of-care treatment did not show any 
significant difference in outcomes [45]. However, a 2013 Phase II study showed that the 
combination of selumetinib and docetaxel acted synergistically, leading to an improved 
OS and PFS compared to placebo and docetaxel [46]. Based on these results, the large 
Phase III (SELECT-1) trial was conducted randomizing 500 patients with KRAS-mutated 
NSCLC to receive either selumetinib and docetaxel or placebo and docetaxel. The 
results, which were published in 2017, showed no significant difference in OS or PFS 
between both treatment groups [47]. 
Pimasertib 
Pimasertib (AS-703026), from Santhera Pharmaceuticals and licensed by Merck 
Serono and Sanofi, is a selective, oral small-molecule MEK inhibitor, which was first 
introduced in 2009 with promising anti-tumor activity in in vitro models. A 2012 Phase I 
study established its safety and recommended a dose of 60 mg twice daily [48]. 
Combination therapy studies have been performed, including a 2015 Phase I study which 
evaluated the combination of pimasertib plus FOLFIRI in patients with KRAS-mutated 
metastatic colorectal cancer; however, the study was limited, as patients were only able 
to tolerate a maximum dose of 45 mg daily due to adverse events of mucositis [49]. More 
promisingly, results were recently published in 2016 of a multicenter Phase II clinical trial 
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evaluating pimasertib compared to dacarbazine in the treatment of cutaneous NRAS 
melanoma. One hundred and ninety-four patients were randomized to pimasertib 60 mg 
twice daily or dacarbazine infusion; the trial found that median PFS was significantly 
longer in patients treated with pimasertib (13.0 vs 6.9 weeks) [50]. 
Binimetinib 
Binimetinib (ARRY-162, MEK-162) by Array BioPharma is a novel orally available 
small molecule MEK inhibitor that was accepted by the FDA in September 2017 for review 
of its New Drug Application [51]. Preliminary data published in 2010 indicated that 
binimetinib is a potent inhibitor of cell proliferation in mutant B-Raf and Ras cell lines and 
has anti-tumor activity in xenograft tumor models across a variety of cancer types 
including colorectal cancer and pancreatic cancer [52]. A Phase I trial was published in 
2017 demonstrating safety and efficacy of binimetinib in 93 patients with biliary cancer, 
KRAS-mutant colorectal cancer, and BRAF-mutant colorectal cancer. The recommended 
treatment dose was 45 mg twice daily. The trial noted dose-limiting adverse events of 
dermatitis acneiform and ocular toxicity, including chorioretinopathy [53]. Further Phase I 
and II trials have evaluated binimetinib with a variety of targeted and chemotherapy 
agents; for example, a 2017 study demonstrated the safety of combined binimetinib and 
FOLFOX in 26 patients with colorectal cancer who previously progressed on standard 
therapies [54]. Currently, the COLUMBUS (encorafenib in combination with binimetinib in 
BRAF-mutant melanoma) and BEACON CRC (encorafenib, binimetinib and cetuximab in 
BRAF-mutant colorectal cancer) are major Phase III trials in progress to evaluate the role 
of binimetinib in advanced cancers [51]. 
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MAPK/ERK Pathway Inhibitors as Combination Therapy by Malignancy 
Melanoma 
Although the use of a BRAF inhibitor as monotherapy in patients with BRAF-
mutant unresectable or metastatic melanoma has been shown to improve OS and PSF 
compared to standard chemotherapy, there are major barriers in clinical use of these 
agents including the development of resistance and/or secondary skin tumors. 
Resistance to these inhibitors is likely due to reactivation of the MAPK/ ERK pathway [55-
57], while the development of secondary skin tumors is the result of BRAF inhibitor-
induced paradoxical MAPK/ERK pathway activation [21,27,58]. Similar to BRAF 
inhibitors, MEK inhibitors have also improved OS of these patients, but do not lead to 
same pitfalls. As a result, the use of MAPK/ERK pathway inhibitors in combination has 
overcome many of the limitations associated with the use of BRAF inhibitors as 
monotherapy. 
Within the past half-decade, the use of BRAF and MEK inhibitors in combination 
therapy has been FDA and European Union approved for the treatment of metastatic 
melanoma patients. The advantage of using the two MAPK/ERK pathway inhibitors in 
combination was first seen with dabrafenib and trametinib in 2014. The approval of this 
combination treatment was based on the multicenter open-label randomized Phase III 
clinical trial enrolling patients with advanced (stage III or IV) BRAF mutant (V600E or 
V600K) melanoma [59]. Patients were randomly selected to receive one of three 
treatment regimens—trametinib 2 mg daily with dabrafenib 150 mg twice daily, trametinib 
1 mg once daily with dabrafenib 150 mg twice daily, or dabrafenib as a single agent 150 
mg twice daily. The patients treated with BRAF/MEK inhibitor combination therapy 
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experienced a higher ORR and PFS compared to the BRAF inhibitor alone. The 
combination-treated group had an ORR of 67% (complete 10%; partial 56%) compared 
to 51% (complete 9%; partial 43%) in the dabrafenib-alone group. The median PFS was 
9.3 versus 8.8 months in the combination and monotherapy groups, respectively. 
In 2015, vemurafenib was approved by the FDA and the European Union for use 
in combination with the MEK inhibitor cobimetinib. The approval of this combination 
therapy was based on the Phase III randomized clinical trial that tested the combination 
treatment on previously untreated patients with metastatic melanoma [60]. In this study, 
all patients first received vemurafenib and were then randomly selected to either receive 
cobimetinib, or placebo. The group receiving combination therapy experienced a 
prolonged PFS compared to the vemurafenib alone group—9.9 and 6.2 months after 
starting treatment, respectively. Additionally, patients who were treated with combination 
therapy lived longer and had complete or partial response to treatment compared to the 
patients treated with BRAF inhibitor monotherapy. The ORR was 68% in 
vemurafenib+cobimetinib treated patients, with a completed response in 10% of patients. 
In vemurafenib-placebo-treated patients, there was an ORR of 45%, with a complete 
response in 4% of patients. Additionally, there was an improvement in the survival rate at 
9 months from 73% in the control group to 81% in the combination therapy group. From 
this study, it was determined that the administration of the BRAF and MEK inhibitors 
vemurafenib and cobimetinib in combination provides metastatic melanoma patients with 
increased efficacy over a BRAF inhibitor alone. 
Since the approval of these MAPK/ERK pathway inhibitor combinations, the 
landscape for treatment of metastatic melanoma has shifted drastically. It is important to 
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emphasize that these trials not only show that BRAF and MEK inhibitors used together 
are effective, but also mitigate the AEs of these agents when used alone—specifically 
secondary skin tumors. In the 2014 Phase III trial, only 2% of patients given the 
dabrafenib-trametinib combination developed cutaneous SCCs compared to 9% of 
dabrafenib-only patients [59]. Similarly, the vemurafenib+cobimetinib combination 
resulted in fewer occurrences (2%) than vemurafenib alone (11%) [60]. 
In addition to these approved BRAF and MEK inhibitor combinations, another 
BRAF and MEK inhibitor combination in the pipeline for FDA approval is encorafenib and 
binimetinib. The two-part Phase III trial of these agents (COLUMBUS) demonstrated that 
the combination of encorafenib and binimetinib improves ORR and PFS of metastatic 
melanoma patients, as well as lowers the incidence of severe AEs. The first part of the 
study measured various endpoints (e.g. ORR, PFS, AEs) of encorafenib+binimetinib, 
encorafenib alone, and vemurafenib alone [61]. The ORR was highest in the combination 
group at 63% (complete 8%; partial 55%), followed by encorafenib alone at 51% 
(complete 5%; partial 45%), and lowest in vemurafenib alone at 40% (complete 6%; 
partial 35%). The PFS was 14.9 months in the combination group, whereas the BRAF    
inhibitors alone were 9.6 and 7.3 months in encorafenib and vemurafenib, respectively.  
In addition to improved outcomes with BRAF/MEK inhibitor combination therapy, 
exposure time to the targeted agents was also extended (combination 51 weeks, 
encorafenib 31 weeks, and vemurafenib 27 weeks). The second part of the study focused 
on the contribution of binimetinib to the combination therapy [62]. At the end of the trial, 
PFS was extended from 7.4 months in encorafenib-alone to 12.9 months in 
encorafenib+binimetinib combination. The ORR was also improved from 50 to 66% in 
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encorafenib alone and encorafenib+binimetinib combination, respectively. With the recent 
publishing of the Part 2 results in September 2017, it is without question that BRAF/MEK 
inhibitor combinations are advantageous alternatives to MAPK/ERK pathway inhibitors 
as monotherapies. Additionally, the use of BRAF and MEK inhibitors in combination with 
immunotherapies has gained a substantial amount of support in the field [63]. 
Immunotherapy, such as anti-PD1 (programmed cell death protein 1) and CTLA-4 
(cytotoxic T-lymphocyte associated antigen 4) antibodies, and BRAF/MEK inhibitors are 
currently considered first-line agents in the treatment of metastatic/advanced-stage 
melanoma. Consequently, there is interest in investigating whether these agents can be 
used safely and efficaciously in combination therapy. Unfortunately, a 2013 Phase I study 
on the combination of vemurafenib and the CTLA-1 antibody ipilimumab in 12 BRAF-
mutated melanoma patients was terminated prior to Phase II investigations due to dose- 
limiting toxic elevations in hepatic enzymes in more than 50% of patients at both the full 
approved doses and at a lower dose of vemurafenib [64]. However, a more recent Phase 
I study (KEYNOTE-022 study) was released in 2017 evaluating the combination of the 
PD-L1 inhibitor pembrolizumab, dabrafenib, and trametinib, in 15 patients with metastatic 
BRAF-mutated melanoma. In these patients, there was a 20% rate of dose-limiting 
toxicities related to elevations in hepatic enzymes; in all patients, these elevations 
normalized with pauses in therapy. Overall, patients demonstrated promising responses, 
with one patient showing a complete response, nine patients showing partial responses, 
and two patients with stable disease. The trial is currently in Phase II [65]. An additional 
Phase II study evaluating the combination of cobimetinib, vemurafenib, and the PD-L1 
inhibitor atezolizumab and a Phase III study evaluating the combination of dabrafenib, 
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trametinib, and the novel PD-1 inhibitor PDR001 are currently underway. If successful, 
these studies have the potential to dramatically alter the current paradigm of care in 
patients with advanced-stage melanoma (ClinicalTrials.gov Identifier: NCT02902029; 
NCT02967692). 
Non-Small Cell Lung Cancer 
In the last few years, many studies have been completed to establish the possible 
role of BRAF inhibitors in the treatment of NSCLC [66-68]. An estimated 2.6% of NSCLCs 
have BRAF mutations [67]. Key in vitro experiments first demonstrated that treatment with 
dabrafenib and trametinib significantly inhibited cell growth in BRAF-mutated NSCLC 
cells. This led to a 2016 Phase II multicenter international study to determine the efficacy 
of this combination therapy (dabrafenib and trametinib) in the treatment of patients with 
BRAF-mutated stage IV NSCLC [67]. In this study, 57 patients with BRAFV600E-mutant 
metastatic NSCLC previously treated with platinum-based systemic therapy were 
enrolled and treated with the combination of dabrafenib (150 mg twice daily) and 
trametinib (2 mg once daily) for multiple 21-day cycles until disease progression was 
noted. The results of the study indicated that 63.2% of patients demonstrated complete 
or partial response to treatment with a median PFS of 9.7 months [67]. By comparison, 
literature evaluating the prior standard of care estimated the response rate and median 
PFS for this chemotherapy regimen in the treatment of BRAF-mutated NSCLC patients 
to be 9% and 3.1 months, respectively [66]. Of note however, in this combination trial 
more than half of patients (56%) experienced a more serious grade 3 or 4 adverse event 
(SAE) and nearly all patients experienced some AE. Despite these SAEs, only 12% of 
patients required discontinuation of the trial due to these toxicities [68]. Accordingly, in 
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2017, the FDA and the European Union approved the combination of dabrafenib and 
trametinib for treatment of patients with metastatic NSCLC with BRAFV600E mutations [69]. 
Colorectal Cancer 
The use of BRAF inhibitors in the treatment of colorectal cancer has a long history 
of investigation. Unlike treatment of BRAF-mutated melanomas, very rapid resistance and 
reactivation of the downstream MAPK/ERK pathway occurs in BRAF-mutated colorectal 
cancer cells, rendering single-agent treatment with BRAF inhibitors virtually ineffective 
[70]. However, some evidence exists supporting the utility of combining vemurafenib with 
other chemotherapy agents. A 2015 study suggested some benefit of combination 
therapy with vemurafenib and panitumumab, an EGFR inhibitor approved by the FDA in 
2006 for patients with metastatic colorectal cancer with disease progression despite prior 
treatment [71]. In this study, 15 metastatic colorectal cancer patients with BRAFV600E 
mutations were enrolled; all patients had previously failed standard chemotherapy 
treatment. The combination of vemurafenib and panitumumab initially resulted in tumor 
regression in 10 out of 12 patients; however, the authors noted that this response was 
modest with all patients having disease progression within one year [71]. 
However, a chemotherapy regimen that has shown more promise in the treatment 
of metastatic BRAF-mutated colorectal cancer is combining vemurafenib, irinotecan, and 
cetuximab. Similar to panitumumab, cetuximab is an EGFR inhibitor approved by the FDA 
for treatment of metastatic colorectal cancer in conjunction with standard chemotherapy 
such as irinotecan [72].  In preliminary in vitro studies, the combination of vemurafenib, 
cetuximab, and effect augmentation with irinotecan was more effective in the treatment 
of colorectal tumor cells with BRAF mutations than any of the individual drugs alone [73]. 
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Based on these findings, a 2016 study enrolled 19 patients with mutated BRAFV600E 
metastatic colorectal cancer and treated them with the combination of cetuximab, 
irinotecan, and vemurafenib [74]. Results from this study demonstrated tumor regression 
radiographically in over one-third (35%) of patients. Based on these outcomes, a large 
Phase II study enrolled 106 patients with BRAF-mutated metastatic colorectal cancer who 
were randomized to receive irinotecan and cetuximab with or without vemurafenib 
(ClinicalTrials.gov; NCT02164916). Interim results of the study released in 2017 
demonstrated that the addition of vemurafenib significantly increased PFS from 2.0 to 4.4 
months and improved disease control rate from 22 to 67% [75]. 
Thyroid Cancer 
To date, there are no approved MAPK/ERK pathway combination therapies for use 
in thyroid carcinomas. Despite this, there are some ongoing Phase I clinical trials testing 
the therapeutic potential of a MAPK/ERK pathway inhibitor used in combination with 
another therapeutic intervention. For example, a pilot study is testing the effect of 
vemurafenib plus the biological agent KTN3379 in BRAF-mutant radioiodine refractory 
thyroid carcinoma patients. The primary endpoint of this study will measure if the 
combination can increase tumoral radioiodine incorporation. In addition, standard safety 
and tolerability are outcomes that are being assessed in this early study 
(ClinicalTrials.gov Identifier: NCT02456701). Additionally, there is another ongoing Phase 
I study testing the use of dabrafenib and lapatinib, the dual HER2/neu and EGFR inhibitor, 
in unresectable radioiodine refractory thyroid cancer patients (ClinicalTrials.gov Identifier: 
NCT01947023). 
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Mechanisms of Resistance to MAPK/ERK Pathway Inhibitors 
MAPK/ERK pathway inhibitors have proven to be effective treatments in various 
cancer types, but the major clinical problem faced with these targeted therapies is the 
emergence of resistance soon after the start of treatment. An initial strategy to overcome 
resistance to BRAF inhibitors involved adding another MAPK/ERK pathway inhibitor 
targeting the serine/threonine kinase, MEK. The rationale behind adding another 
MAPK/ERK pathway inhibitor to the treatment strategy is based on pathway reactivation 
[16,21-23]. When given alone, BRAF inhibitors can induce the pathway to become 
activated evading the blockade. By adding in an inhibitor of a downstream effector (e.g., 
MEK) you are targeting two nodes of the pathway increasing its inhibition. Since the 
preceding section focused extensively on the use of MAPK/ERK pathway inhibitor 
combination therapies in various cancers, we will review the postulated mechanisms of 
resistance to MAPK/ ERK pathway inhibitors, namely in inhibitors of BRAF. It is important 
to note that mechanisms of BRAF inhibitor resistance can vary within an individual type 
of cancer, as well as between different malignancies. For example, it cannot be assumed 
that all melanoma patients who develop resistance to a given BRAF inhibitor have the 
same underlying mechanism. There are various modes that can attribute towards 
resistance, but one thing that is shared amongst these patients is the median time to 
resistance — 6–8 months after the start of treatment [76,77]. As with any type of 
resistance, BRAF-inhibitor resistance can be primary (intrinsic) and/or secondary 
(acquired) (Figure 1-1). 
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Primary (Intrinsic) Resistance 
Despite the large majority of metastatic melanoma patients who present with the 
activating BRAF mutation (V600E or V600K), 20% of these patients are initially refractory 
to selective BRAF inhibitors and do not respond [76]. Similarly, there is a subset of 
metastatic colorectal cancer patients who have the BRAF mutant (<10%) and do not 
respond to BRAF inhibitors [78]. In melanoma, mechanisms of intrinsic resistance can 
include, but are not limited to: RAC1 mutations, loss of PTEN, dysregulation of cell-cycle 
proteins, and changes to the microenvironment. In colorectal cancers harboring the same 
BRAF mutation, intrinsic resistance to these inhibitors is primarily due to feedback 
activation of EGFR [79]. 
The RAC1P29S mutation is the third most common hotspot mutation present in 
metastatic melanoma patients, followed by the second most common NRASQ61, and the 
most common being BRAFV600 [80]. RAC1 is a member of the RAS GTPase superfamily 
and has an integral role in cell motility and growth. Its exact role in melanogenesis is not 
fully understood, but evidence supports that RAC1 is a key player in epithelial 
mesenchymal transition (EMT) [81-84]. Unlike BRAF and NRAS mutations, the RAC1 
hotspot mutation is recognized as a UVB (sunlight)-induced DNA damage (e.g. C  T 
transition in dipyrimidine). This mutation keeps the GTPase in a mostly active state—
compared to mutant isoforms of RAS, which are constitutively active—through increased 
GDP  GTP exchange [80]. Moreover, melanoma cell lines that possess the RAC1P29S 
somatic mutation have been shown to be resistant to BRAF inhibitors [85]. In this study, 
Watson and colleagues showed that the expression of mutant RAC1 in melanoma cell 
lines lead to increased cell viability and decreased apoptosis in vitro and enhanced tumor 
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growth in vivo when treated with BRAF inhibitors constituting resistance. Interestingly, 
when the RAC1 mutant was silenced and cells still expressed mutant BRAF, sensitivity 
to the kinase inhibitors was increased [85]. 
Additionally, the loss of PTEN in melanoma not only contributes to tumorigenesis 
in melanoma patients, but can contribute to BRAF inhibitor resistance [86,87]. PTEN gene 
is a tumor suppressor gene that encodes a phosphatase responsible for 
dephosphorylating products of PI3K. Loss of this protein results in decreased apoptotic 
and increased mitogen pathway signaling due to increased phosphorylation of AKT. This 
can be reversed with the addition of PTEN to cells deficient of the protein [88,89]. In 2011, 
Paraiso and colleagues showed that the loss of PTEN contributed to BRAF-inhibitor 
resistance through changes in expression of BIM, a pro-apoptotic regulator [90,91]. When 
a BRAF inhibitor was used to treat melanoma cells without PTEN there is an increase in 
AKT signaling compared to cells that do express the phosphatase. This increase led to 
decreased apoptosis, which was determined to be mediated by expression of BIM. The 
increased expression of BIM correlated to cells that expressed PTEN, whereas BIM 
expression was suppressed in cells not expressing PTEN. To confirm the contribution of 
BIM, knockdown studies of the protein were conducted and in cells expressing PTEN, the 
siRNA of BIM led to abrogated apoptosis [91]. Not only can loss of PTEN contribute to 
intrinsic BRAF-inhibitor resistance, but it has also been shown that loss-of-function 
mutations can also be a mechanism of resistance [92]. 
The dysregulation of a critical cell-cycle regulator, CDK4, is suggested to be 
another intrinsic mode of resistance to BRAF inhibitors [93]. More specifically, this positive 
regulator of cell-cycle progression is found to have activating mutations in a large subset 
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of metastatic melanoma patients, therefore rendering them nonresponsive to targeted 
treatment. The active CDK4 protein phosphorylates RB (retinoblastoma protein), which 
promotes the transition of a cell from the G1 phase to S phase of the cell cycle. CDK4 is 
also responsible for phosphorylating other proteins critical in cell-cycle progression and 
inhibition of apoptosis and/or cell senescence [92]. Interestingly, when another cell-cycle 
regulator, cyclin D1, is overexpressed in cells also expressing mutated CDK4, BRAF 
inhibitor resistance is seen [94]. 
A unique feature of CRC patients with BRAF mutants is their primary resistance to 
BRAF inhibitors. Despite these patients carrying the activating BRAFV600 mutation, the 
selective inhibitors are not effective as they are in melanoma patients carrying the same 
mutant [95]. The general mechanism is the feedback activation of the MAPK/ERK 
pathway through EGFR. Studies using a BRAF inhibitor in combination with an antibody 
or small-molecule inhibitor targeting this growth-factor receptor have shown optimal 
synergism compared to the BRAF inhibitor alone in CRC patients [54]. It is also important 
to emphasize that CRC patients generally have higher expression levels of EGFR than 
melanoma patients, lending some reasoning for the difference in response to BRAF 
inhibitors. Since melanoma patients express a smaller amount of EGFR than CRC 
patients, feedback activation through a growth-factor receptor is not a mode of resistance 
to the BRAF inhibitor [79,95]. 
Secondary (Acquired) Resistance 
For the patients who do initially respond to a BRAF inhibitor but show disease 
progression a few months after the start of treatment, the resistance mechanisms can be 
generally classified as MAPK/ERK pathway dependent or independent. In the two 
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following subsections, we will discuss various modes of resistance that fall into each of 
these categories focusing on those most prevalent in melanomas. 
MAPK/ERK Pathway Dependent 
Resistance mechanisms that are dependent on this signaling pathway include 
somatic activating mutations of NRAS, an isoform of the GTPase upstream of BRAF. As 
mentioned previously, activating mutations of NRAS contribute to paradoxical 
MAPK/ERK pathway activation through dimerization of CRAF [2,3,6]. Additionally, there 
are alterations made directly to BRAF itself such as truncation, amplification, or fusion of 
the protein kinase. In the instance of the latter, it has been reported that the AGAP3- 
BRAF or various other fusion genes are strong contributors to acquired resistance in 
melanoma patients [96,97]. Moreover, it has been shown that despite having BRAF fusion 
genes, these melanomas are still sensitive to MEK inhibitors in combination with a PI3K 
inhibitor or CDK4/6 inhibitor [96]. When changes are made to BRAF, it develops the ability 
to ‘‘escape’’ inhibition by selective small molecules such as vemurafenib, dabrafenib, and 
encorafenib. Downstream of BRAF, modifications can be made to the MAPK/ERK 
pathway that ultimately lead to resistance against BRAF inhibitors. In some instances, 
MEK mutations can occur that render the kinase constitutively active and can 
subsequently activate ERK [98]. There have been some reported cases that show the 
activation of ERK in a MEK-independent manner by another protein kinase, COT 
(MAP3K8; mitogen activated protein kinase 8) [99]. In the MAPK/ERK pathway-
dependent modes of resistance, cellular processes like immune response, cell-cycle 
regulation, and angiogenesis are affected in a manner that promotes tumor cell 
maintenance. Although this drug-resistance favors cancer progression, it also provides 
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researchers with the opportunity to develop therapies that target these aberrant cellular 
processes. Examples of this include application of cutting-edge immunotherapies such 
as the immune checkpoint inhibitors of PD-L1 and CTLA-4, as well as cyclin dependent 
kinase 4 (CDK4) and vascular endothelial growth factor receptor (VEGFR) inhibitors to 
antagonize cell-cycle progression and angiogenesis, respectively [100-102]. 
MAPK/ERK Pathway Independent 
Alternatively, resistance to BRAF inhibitors can occur in a MAPK/ERK pathway-
independent manner. In such instances, RTKs can be overexpressed or other signaling 
pathways can be upregulated [103]. Overexpression of RTKs and their respective RTK 
ligands (e.g. EGF and EGFR, PDGF and PDGFR) are commonly observed [104]. The 
PI3K/AKT signaling pathway is most often upregulated to compensate for the blockade 
of the MAPK/ERK pathway [105,106]. In this pathway, various insults can be made that 
promote its increased signaling. The activity of AKT is tightly regulated by the 
phosphatase, PTEN. Upon phosphorylation by PI3K, AKT becomes activated and acts 
on its downstream effectors such as mTOR and GSK. Activity of Akt can be reversed via 
phosphate removal by PTEN. In a resistant state, PTEN has been reported to harbor 
inactivating mutations that lead to the phosphorylation of AKT and subsequent pathway 
activation [89]. This signaling cascade can also be altered to promote BRAF inhibitor 
resistance with the amplification of AKT. Due to the crosstalk to the MAPK/ERK and 
PI3K/AKT pathways, one approach to overcome resistance is the combination of 
inhibitors of each pathway. There is a breadth of preclinical and clinical data supporting 
this approach [107,108]. 
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Novel Approach to Overcoming BRAF Resistance 
As resistance to BRAF inhibitors has developed into a more clinically relevant 
problem, deciphering these resistance mechanisms has become a critically important 
strategy to identify novel methods to overcome them. Given the many pathways for BRAF 
inhibitor resistance, simultaneously targeting of these multiple pathways at once to 
ultimately overcome resistance would be an ideal strategy. A representative example of 
this multi-pathway approach is the use of novel heat shock protein 90 (Hsp90) inhibitors. 
Hsp90 is a molecular chaperone that functions as the hub of proteostasis for many cellular 
proteins. The activity of this chaperone assures proper protein folding and stability, 
therefore playing a major role in their function [109]. The substrates of Hsp90 are referred 
to as ‘‘clients’’ and are involved in a vast range of cellular processes. Interestingly, many 
of the proteins involved not only in cancer development and maintenance, but also BRAF 
inhibitor resistance are all clients of Hsp90 chaperone function [110]. This highlights the 
prospect of simultaneously targeting multiple signaling pathways through the inhibition of 
this molecular chaperone. While early Hsp90 inhibitors such as geldanamycin and 17-
AAG were trialed in melanoma and thyroid cancer (ClinicalTrials.gov Identifier: 00087386) 
patients in Phase II, they never progressed to Phase III given the hepatotoxicity observed 
with treatment [111]. This toxicity was believed to be due to a dose-escalation effect 
resulting from upregulation of Hsp70 as a secondary effect of the heat shock response 
induced by Hsp90 inhibition. Given the pro-survival processes Hsp70 regulates, it 
counteracted the inhibitory effects of Hsp90 inhibition requiring higher doses to maintain 
the inhibitory effect until a dose-limiting toxicity had occurred. Novel Hsp90 inhibitors in 
more advanced clinical and preclinical studies that do not induce this significant heat 
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shock effect may be on the horizon as a novel strategy to overcome BRAF resistance in 
several tumors [112,113]. Some of these have moved into Phase III trials such as 
retaspimycin and ganetespib as combination therapies but have not been FDA approved. 
Other preclinical and early clinical strategies in development involve combinations of 
immunotherapy agents with BRAF or MEK inhibitors, histone deacetylase inhibitors with 
BRAF inhibitors, and check-point inhibitors combined with BRAF/MEK inhibition 
[114,115]. Further translational and clinical testing will be needed to define which of these 
strategies may be the most successful in overcoming this resistance problem. 
 
Clinical Applications of BRAF and MEK Inhibitors 
Standard of Care 
Melanoma 
The current National Comprehensive Cancer Network (NCCN) guidelines for the 
treatment of unresectable metastatic melanoma offer patients and clinicians a wide range 
of options. For patients with brain metastases, treatment historically involved radiation 
therapy with or without palliative resection. However, this paradigm has been rapidly 
shifting due to the development of BRAF inhibitors and immunotherapy. Emerging 
evidence suggests that BRAF inhibitors may have an important role in the treatment of 
patients with brain metastases as an adjunct to radiation. A 2012 Phase II study treated 
172 patients with metastatic BRAF-mutated melanoma and at least one brain metastases 
with dabrafenib; of patients with BRAFV600E mutations who had never received local 
treatment for brain metastases, 40% achieved and overall intracranial response. Of the 
patients who had previously received local treatment (surgery, whole-brain radiotherapy, 
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or stereotactic radiosurgery), the overall intracranial response rate was 31% [116]. To 
further investigate this potential therapeutic strategy, an upcoming Phase II trial will aim 
to investigate the concurrent roles of dabrafenib and trametinib with stereotactic radiation 
(ClinicalTrials.gov Identifier: NCT02974803). For patients without brain metastases, 
options include systemic therapy, intralesional injections, palliative surgical resection, 
radiation, or palliative supportive care. First-line systemic therapies for non-resectable 
metastatic melanoma include immunotherapy, clinical trials, and for the large subset of 
patients with BRAFV600E mutations, treatment includes either the combination of 
dabrafenib and trametinib or vemurafenib and cobimetinib. Other systemic therapies are 
broader and include traditional cytotoxic agents such as dacarbazine and paclitaxel, high-
dose IL-2, imatinib (if a c-Kit mutation is present), temozolomide, vinblastine, nitrosourea, 
and interferon alpha-2b; all of these options are very rarely used in current clinical practice 
and only if no other options including clinical trials are available to the patient. In general, 
patients are nearly always treated with immunotherapy or targeted therapy [117]. 
Differentiated Thyroid Cancer 
The current NCCN guidelines for the treatment of metastatic differentiated thyroid 
cancer relies heavily on radioactive iodine treatment. However, there are a subset of 
patients with persistent disease, locoregional recurrence, or distant metastases that do 
not uptake iodine. In these patients, the recommendation is to suppress TSH levels with 
levothyroxine treatment. Additionally, options include resection or treatment with radiation 
therapy, surveillance only in asymptomatic patients with slow disease progression, 
treatment with non-FDA-approved small molecule inhibitors, or treatment with lenvatinib 
or sorafenib for disease that has failed these other options. Cost and side-effect profiles 
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of these inhibitors must be weighed as part of the risk/benefit analysis and treatment 
should always be performed on an individual basis [118]. 
Metastatic Colorectal Cancer 
The current NCCN guidelines offer many chemotherapy options for the treatment 
of metastatic colorectal cancer. First-line or initial therapy includes FOLFOX, CAPEOX, 
FOLFIRI, FOLFOXIRI, 5FU/leucovorin, or capecitabine, all plus or minus bevacizumab. 
In patients with KRAS/NRAS wild-type and left-sided tumors, treatment options expand 
to include FOLFOX or FOLFIRI plus cetuximab or panitumumab. To date, there are no 
NCCN-recommended chemotherapy regimens that include BRAF or MEK inhibitors 
[119]. 
NSCLC 
The current NCCN guidelines for the treatment of stage IV metastatic NSCLC 
depend on the initial determination of EGFR, ALK, ROS1, and PD-L1 tumor markers. If 
the patient is found to have a sensitizing EGFR mutation, first-line treatment is with 
erlotinib, afatinib, or gefitinib. If the patient has ALK rearrangement, first-line treatment is 
with crizotinib or ceritinib, and if the patient has ROS1 rearrangement, first-line therapy is 
with crizotinib. If the patient is PD-L1 expression positive, first-line therapy is with 
pembrolizumab. For all other patients or those who demonstrate disease progression with 
the above therapies, first-line therapy is with doublet chemotherapy (typically cisplatin or 
carboplatin-based). Very recently in 2017, the combination therapy of dabrafenib and 
trametinib has been approved by the FDA for the treatment of BRAF-mutated NSCLC 
[120]. 
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Hairy Cell Leukemia  
The current NCCN guidelines for the treatment of patients with HCL recommend 
initial chemotherapy with the purine analogs cladribine or pentostatin. If there is less than 
complete response or relapse at less than a year, options include treatment with a purine 
analog plus or minus rituximab, interferon alpha, or rituximab alone. The current 
recommendation for any progression despite these therapies is treatment with 
vemurafenib plus or minus rituximab, or ibrutinib [121]. 
Common or Noted Side Effects of BRAF and MEK Inhibitors 
Vemurafenib 
The most common side effects are dermatological, including skin rash and 
photosensitivity [122]. Cutaneous SCC or keratoacanthomas develop in 15–30% of 
patients; in the 2011 Phase III trial conducted by Chapman et al., 18% of patients 
developed SCC or keratoacanthomas or both; and all could be treated by simple excision 
[19]. Other adverse events include arthralgia, fatigue, nausea, vomiting, diarrhea, 
neutropenia, peripheral edema, and alopecia [122]. 
Dabrafenib 
The most common side effects are dermatological, including hyperkeratosis, 
papillomas, or palmar-plantar erythrodysesthesia. Between 5 to 20% of patients develop 
cutaneous SCC or keratoacanthoma. Other adverse events include fatigue, headache, 
arthralgia, peripheral edema, nausea, vomiting, diarrhea, and hyperglycemia [123]. 
Sorafenib 
The most common side effects are hypertension, headache, peripheral 
neuropathy, palmar-plantar erythrodysesthesia, alopecia, rash with desquamation, 
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hypocalcemia, fatigue, and weight loss [124]. In the 2014 Phase III study by Brose et al., 
serious adverse effects included secondary malignancy in 4.3% of patients, dyspnea, and 
pleural effusion [32]. 
Trametinib 
The most common side effects are hypertension, cardiomyopathy (7–11%), skin 
rash (8% with grade 3 or 4 rash), dermatitis acneiform, diarrhea, minor bleeding (<1% 
grade 3–4), and peripheral edema.  Rare events include ocular events such as a blurred 
vision, reversible chorioretinopathy, and retinal-vein occlusion/retinal detachment. Of 
note, there are no findings of cutaneous SCC or keratoacanthomas as seen with 
vemurafenib and dabrafenib [32,35,125]. 
Cobimetinib 
The adverse effects of cobimetinib are reported in conjunction with vemurafenib 
treatment. The most common side effects are diarrhea, nausea, vomiting, elevated liver 
enzymes, elevated creatine kinase levels, and central serous retinopathy, as reported in 
the 2014 study by Larkin et al. [60]. Other adverse events include decreased ejection 
fraction, hypertension, dermatologic side effects (rare cutaneous SCC or 
keratoacanthomas), minor hemorrhage (<1% grades 3 or 4), and visual impairment, 
including blurred vision, chorioretinopathy, and retinal detachment (12% overall, 2% 
grades 3 or 4) [126]. 
Selumetinib 
The most common side effects are fatigue, rash, and elevated liver enzymes. 
Other side effects events include nausea, diarrhea, peripheral edema, oral mucositis, 
electrolyte abnormalities, and dyspnea. Most adverse events are grade 1 or 2 [42]. 
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Average Monthly Costs of Selective Inhibitors (Medicare Data) 
Annual monthly costs for selective inhibitors can be seen in Table 1-1. 
 
Conclusion 
The development and approval of BRAF and MEK inhibitors in BRAF-mutant 
cancers has dramatically changed the landscape of treatment options and clinical 
outcomes of cancer patients, especially those with metastatic melanoma. While the initial 
response to these inhibitors is robust, long-term complete responses are rare and most 
patients will develop resistance, leading to disease progression. Additionally, the side-
effect profiles to BRAF inhibitors are of concern due to the risk of developing secondary 
skin tumors, such as cutaneous SCCs. The advent of combination therapy with BRAF 
and MEK inhibitors has eliminated many of the initial concerns associated with BRAF 
inhibitor monotherapy; evidence demonstrates both improved side-effect profiles and 
prolonged clinical endpoints like ORR and PFS. Future treatment strategies involving 
BRAF and MEK inhibitors will aim to overcome currently recognized mechanisms of 
resistance and provide synergistic anti-tumor activity. Excitingly, Hsp90 small-molecule 
inhibitors—especially C-terminal targeted—are on the horizon of being an alternative to 
overcome resistance, and new research supports the role of MAPK/ERK pathway 
inhibitors in combination with other protein or system targets, like CDK4/6 and PI3K or 
immunotherapy, respectively. 
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Tables 
Table 1-1 Average monthly costs for selective inhibitors (Medicare data) 
Drug Cost (US$) 
Vemurafenib $13,021 for 30 day 
Dabrafenib $11,581 for 30 days 
Sorafenib $19,775 for 30 days 
Trametinib $12,753 for 30 days 
Cobimetinib $7,856 for 28 days 
Selumetinib Average wholesale price unavailable 
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Figures 
 
Figure 1-1 MAPK/ERK Pathway 
This signaling pathway is activated when a growth factor (ligand) binds to its respective growth factor receptor. Once 
activated, the RTK transmits the extracellular signal inside the cell via the adaptor protein GRB2. The membrane bound 
GTPase, RAS, then becomes activated by the exchange of GDP for GTP. This is facilitated by the nucleotide exchange 
factor, SOS. Activated RAS then initiates the signaling cascade of MAP kinases. Finally, activated ERK can 
phosphorylate its cytosolic or nuclear effectors. The latter results in changes to transcription and ultimately cell 
proliferation, differentiation, and survival. GRB2: growth factor receptor bound protein 2, ERK (MAPK): extracellular 
signal related kinase, MEK (MAPKK), RAF (MAPKKK): rapidly accelerated fibrosarcoma, RAS: rat sarcoma protein, 
RTK: receptor tyrosine kinase, SOS: son of sevenless. 
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Abbreviations 
AE  adverse events 
AKT  protein kinase B 
ALK  anaplastic lymphoma kinase 
BIM  Bcl-2-like protein 11 
BRAFWT BRAF wild-type 
CAPEOX capecitabine oxaliplatin 
CDK4  cyclin dependent kinase 4 
CMML chronic myelomonocytic leukemia 
COT  MAP3K8; mitogen activated protein kinase 8 
CRC  colorectal cancer 
CTLA-4 cytotoxic T-lymphocyte associated antigen 4 
DTC  differentiated thyroid cancer 
EGF  epidermal growth factor  
EGFR  Epidermal growth factor receptor 
EMT  epithelial mesenchymal transition 
ERK  extracellular signal-related kinase 
FDA  Food and Drug Administration 
FOLFIRI folinic acid fluorouracil irinotecan hydrochloride  
FOLFOX folinic acid fluorouracil oxaliplatin 
FOLFOXIRI folinic acid fluorouracil oxaplatin irinotecan 
FU  fluorouracil  
GDP   guanosine diphosphate  
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GSK  glycogen synthesis kinase 3 
GTP  guanosine triphosphate  
HCL  hairy cell leukemia  
Hsp70  70 kDa heat shock protein 
Hsp90  90 kDa heat shock protein 
IL-2  interleukin-2 
MAPK  mitogen activated protein kinase 
MEK  mitogen activated protein kinase 
MTD  maximum tolerated dose  
mTOR mammalian target of rapamycin 
NCCN  National Comprehensive Cancer Network 
NSCLC non-small cell lung cancer 
ORR  overall response rate 
OS  overall survival  
PD-L1  programmed death ligand 1 
PD1  programmed cell death protein 1 
PDGF  platelet derived growth factor 
PDGFR platelet derived growth factor receptor 
PET  positron emission tomography 
PFS  progression free survival  
PI3K  phosphoinositide 3-kinase  
PTEN  phosphatase and tensin homolog 
RAC1  Ras-related C3 botulinum toxin substrate 1 
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RAF  rapidly accelerating fibrosarcoma 
RAF (A/B/C) RAF isoforms 
RAIR  radioactive iodine refractive 
RAS  rat sarcoma protein 
RAS (H/K/N) RAS isoforms 
RB  retinoblastoma protein 
RCC  renal cell carcinoma  
RP2D  recommended Phase II dose 
RTK  receptor tyrosine kinase  
SAE  serious adverse events 
SCC  squamous cell carcinoma  
TKI  tyrosine kinase inhibitor  
TSH  thyroid stimulating hormone 
VEGFR vascular endothelial growth factor receptor  
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Chapter 2   
Old and New Approaches to Target the Hsp90 Chaperone2 
 
Abstract 
The 90-kDa heat shock protein (Hsp90) is a molecular chaperone that ensures 
cellular proteostasis by maintaining the folding, stabilization, activation, and degradation 
of over 400 client proteins. Hsp90 is not only critical for routine protein maintenance in 
healthy cells, but also during states of cellular stress, such as cancer and 
neurodegenerative diseases. Due to its ability to affect phosphorylation of numerous 
client proteins, inhibition of Hsp90 has been an attractive anticancer approach since the 
early 1990’s, when researchers identified a druggable target on the amino terminus of 
Hsp90 for a variety of cancers. Since then, 17 Hsp90 inhibitors that target the chaperone’s 
N-terminal domain, have entered clinical trials. None, however, have been approved thus 
far by the FDA as a cancer monotherapy. In these trials, a major limitation observed with 
Hsp90 inhibition at the N-terminal domain was dose-limiting toxicities and relatively poor 
pharmacokinetic profiles. Despite this, preclinical and clinical research continues to show 
that Hsp90 inhibitors effectively target cancer cell death and decrease tumor progression 
supporting the rationale for the development of novel Hsp90 inhibitors. Here, we present 
an in-depth overview of the Hsp90 inhibitors used in clinical trials. Finally, we present 
current shifts in the field related to targeting the carboxy-terminal domain of Hsp90 as well 
 
2 This chapter was published in Current Cancer Drug Targets (PMID: 31793427) and completed in 
collaboration with the following authors: Trever R. Carter, Mark S. Cohen, and Brian S.J. Blagg. 
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as to the development of isoform-selective inhibitors as a means to bypass the pitfalls of 
current Hsp90 inhibitors and improve clinical trial outcomes. 
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Introduction 
A vital characteristic of all eukaryotic cells is the requirement for proper molecular 
chaperone function. These chaperone proteins serve as part of a cell’s “quality control 
system” to ensure proteostasis. Specifically, chaperones maintain the folding, stability, 
activation, and degradation of intracellular proteins, ultimately contributing to overall 
cellular homeostasis [1]. Proteins that depend upon and/or interact with these molecular 
chaperones are called clients. Chaperone function is not only important for routine client 
maintenance, but also in response to cellular stress. In certain disease states, like cancer 
and neurodegenerative diseases, proteins are often misfolded, leading to aggregation, 
which increases the cellular dependence upon chaperone function [2]. In light of this, 
there is a significant amount of interest to design and develop novel therapeutics that 
target molecular chaperones, specifically the heat shock protein (Hsp) family. 
The Hsp family of molecular chaperones was first observed in Drosophila 
melanogaster by Ritossa in the early 1960s as a result of a heat-induced change to 
chromosome appearance [3]. In the D. melanogaster cells, certain regions of 
chromosomes gained “puff sites” where there was an increase of RNA synthesis and 
subsequent changes to the pattern of protein expression [4-6]. Interestingly, a small 
subset of these proteins accounted for the majority of proteins with increased expression 
and was accordingly named heat shock proteins [7]. Since their discovery and 
characterization, expression levels of these chaperones are not only increased in 
response to heat, but other environmental stressors as well, such as inflammation, 
hypoxia, infection, and/or nutrient deprivation. This increase in Hsp expression is the 
result of the heat shock response (HSR) that is mediated by the transcription factor heat 
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shock factor-1 (HSF1) binding to its transcriptional element, the heat shock element 
(HSE) [8]. The Hsp family consists of a multitude of chaperones named according to 
molecular weight. In regard to novel therapeutic agents, inhibitors that disrupt the 90-kDa 
Hsp (Hsp90) function are at the forefront of development and exhibit high potential for 
clinical use in humans and more specifically, the treatment of cancer. 
Hsp90 accounts for 1-2% of total protein concentration in unstressed cells, 
whereas chaperone expression levels increase to ~4-6% in response to cellular stress as 
a means to handle the increased demand for client protein stabilization [1,9]. Regardless 
of cellular state, Hsp90 clientele includes a variety of proteins involved in several cellular 
processes and pathways, such as protein kinases, cell cycle regulators, transcription 
factors, and steroid hormone receptors, to name a few [10]. Interestingly, in the stressed 
state, which is common to malignancies, Hsp90 serves as a chaperone to numerous 
proteins that maintain the ten hallmarks of cancer [11,12]. Taken together, these points 
highlight the opportunity that Hsp90 chaperone inhibition simultaneously targets multiple 
oncogenic pathways and proteins. 
In the early 1990s, Whitesell and colleagues demonstrated Hsp90’s crucial role in 
oncogenic transformation by serendipitously inhibiting chaperone function with a 
benzoquinone ansamycin, geldanamycin (GDA), which initiated the concept of chaperone 
inhibition [13]. Prior to this finding, it was mechanistically unclear how oncogenic gene 
products, like tyrosine kinases and more specifically v-src, promoted the transformation 
of healthy cells into malignant ones [14]. GDA was presumed to be a tyrosine kinase 
inhibitor until Whitesell and colleagues showed that it bound to Hsp90 in a stable and 
specific manner. This binding not only disrupted the formation of the Hsp90-src 
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heteroprotein complex, but it also inhibited transformation, highlighting the dependence 
of the cell on Hsp90 during oncogenesis [15]. Since this pivotal finding, Hsp90’s function 
and role in oncogenesis have been more well-defined, leading to the development of 
several compounds that target and inhibit the chaperone. Of these inhibitors, a handful 
have entered clinical trials for the treatment of cancer, but none yet have been approved 
for use as anti-neoplastic agents [16]. 
Although the need for Hsp90’s function has mostly been recognized in cancer, the 
molecular chaperone also plays an integral role in the pathogenesis of neurodegenerative 
diseases characterized by protein aggregation, such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) [17]. Interestingly, the proteins most implicated in protein 
aggregation in AD and PD are Hsp90 clients – β-amyloid (Aβ) peptide and tau and α-
synuclein, respectively. For example, two hallmark indicators of AD are extracellular 
plaque deposits of Aβ and hyperphosphorylated tau [17,18]. In PD, α-synuclein is 
recognized as a genetic and pathological link to disease progression. More specifically, 
this protein is found deposited in Lewy bodies which are abnormal aggregates formed in 
presynaptic nerve terminals [19,20]. Unlike malignancies, where inhibition of Hsp90’s 
function is ideal for treatment, it has been suggested that neurodegenerative diseases 
would benefit most from the upregulation of chaperone function to increase its 
cytoprotective role and ultimately decrease protein aggregation [17]. While the 
development of Hsp90 treatments for AD and PD is warranted, we will focus the 
remainder of our insights on Hsp90 therapeutic approaches in the context of 
malignancies. 
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Here, we provide a comprehensive, up-to-date evaluation of the Hsp90 inhibitors 
that have entered clinical trials, specifically in malignancies, as well as some observations 
as to why they have not yet achieved FDA approval. From these observations in trials, 
researchers have now shifted to alternative approaches to Hsp90 inhibition, including 
targeting the carboxy terminal domain as well as characterizing and developing isoform 
specific Hsp90 inhibitors that can then be selectively targeted in certain disease states. 
Hsp90 Family of Proteins 
The mammalian Hsp90 family of proteins is highly conserved and includes four 
members or isoforms. These proteins are indirectly involved in several cellular processes 
and found in distinct cellular compartments. In addition to Hsp90’s function as a molecular 
chaperone, it serves an essential role in overall cellular homeostasis [10,21,22]. The 
majority of Hsp90 isoforms are located in the cytoplasm and in the HSP90A subfamily, 
which includes inducible Hsp90α and constitutively expressed Hsp90β isoforms. Also, 
there are the HSP90B and TRAP subfamilies that include the Grp94 isoform in the 
endoplasmic reticulum and TRAP1 isoform in the mitochondria, respectively [22]. The 
three Hsp90 subfamilies, their five gene products, and respective cellular locations are 
listed in Table 2-1. Despite occupying different cellular compartments, all isoforms share 
a very similar sequence and structural homology, which are important to understand in 
order to better evaluate and critique the challenges of current Hsp90 inhibitors. 
The family of molecular chaperones is biologically active as homodimers with each 
monomer made up of three structurally and functionally distinct domains: N-terminal, 
middle, and C-terminal domains (Figure 2-1) [21]. The N-terminal domain (NTD) is the 
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site for nucleotide binding and ATPase activity [23]. The middle domain (MD) also plays 
an important role in the hydrolysis of ATP to ADP – namely, the Arg380 residue, which is 
part of the catalytic loop for hydrolysis [24]. The NTD and MD are connected or tethered 
to each other via a charged linker region. Lastly, the C-terminal domain (CTD) is the site 
for protein dimerization and additional ATP binding [25]. The CTD contains a 
tetratricopeptide repeat (TPR) motif that increases binding specificity for its substrates, 
especially co-chaperones with similar TPR-motifs. All three regions have been reported 
to bind clients and co-chaperones.  
All inhibitors that have undergone clinical investigation as anticancer drugs, target 
the NTD and bind competitively to its ATP binding site. Although effective and potent at 
killing cancer cells preclinically, in clinical trials detrimental dose-limiting toxicities (DLTs) 
and dose scheduling limitations have prevented NTD Hsp90 inhibitors from gaining FDA 
approval [26]. One speculation in the field regarding the failure of NTD compounds in 
clinical trials due to DLTs is that NTD targeting leads to a “pan-inhibitory” effect against 
all Hsp90 isoforms and induces the HSR, leading to a pro-survival effort by the cell that 
in turn requires a higher dose of inhibition of Hsp90 to achieve the same cancer cell 
suppressive effect thereby resulting in progressive dose escalation, and over time, DLTs 
[21,27,28]. Although this remains a major obstacle in the clinic, recent findings at the 9th 
International Conference on the Hsp90 Chaperone Machine (ICHCM) suggest a new 
approach to target the chaperone which could decrease DLTs. At the conference, Dr. 
Brian Blagg presented two newly designed scaffolds of Hsp90β isoform-selective 
inhibitors that promoted degradation of HSF1 and ultimately led to no HSR induction [29]. 
This novel approach will be revisited in a subsequent section of the manuscript. As of 
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February 2019, more than 170 clinical trials have taken place to test 18 different Hsp90 
inhibitors and their potential uses as therapeutic agents in humans [see 
ClinicalTrials.gov]. Although the majority of trials are seen through to completion, more 
than half do not progress past Phase I (Figure 2-2). In the following section, we present 
a comprehensive description of these chaperone inhibitors in clinical trials to date, in order 
to highlight their strengths and weaknesses. Additionally, we provide insight and 
recommendations to improve the development of novel Hsp90 inhibitors as anticancer 
agents. 
Clinical Landscape of Hsp90 Inhibitors 
For over 25 years, the development of Hsp90 inhibitors has predominantly 
centered around the design of drug com- pounds that competitively bind the N-terminal 
ATP-binding sites to disrupt molecular chaperone function [21,30]. Moreover, all four 
Hsp90 isoforms share high sequence identity in this region, which decreases the potential 
to selectively target a specific isoform. This form of pan-inhibition, wherein all isoforms 
are non-selectively inhibited, has been thought to represent a major limitation in the 
clinical development and approval of these inhibitors as anticancer agents. For cancer 
cells, optimal inhibitors should selectively target the cytosolic isoforms Hsp90α and 
Hsp90β, however this has been very difficult as these isoforms share >95% sequence 
identity in the NTD. Perhaps by gaining a better understanding of the chaperone’s 
enzyme kinetics, it could help to distinguish each isoform and lead to the generation of 
more durable and effective Hsp90 inhibitors. Lee et al. eloquently present Hsp90 as being 
a “perfect enzyme” due to the chaperone having an ATP hydrolysis rate of ~1 s-1. 
Although demonstrated in Escherichia coli, this work emphasizes the indispensable value 
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of gaining a mechanistic understanding of the ATPase activity, especially before 
optimizing inhibitors that disrupt its function [31]. The 18 Hsp90 inhibitors are 
characterized by five chemical structure-based categories: (i) natural products and their 
derivatives, (ii) purine-based, (iii) benzamide, (iv) resorcinol-containing, and (v) 
miscellaneous. The following five sections give an in-depth evaluation of Hsp90 inhibitors 
that have entered clinical trials. 
Natural Products and their Derivatives 
As mentioned above, in the early 1990s Whitesell and colleagues identified GDA 
as a ligand of Hsp90, and years later, demonstrated its binding to the N-terminal ATP- 
binding site. Upon GDA binding, ATPase activity of the molecular chaperone is disrupted 
and subsequently client-protein stabilization, which results in client protein degradation 
and an attack on multiple cellular processes [32]. GDA is a 1,4-benzoquinone ansamycin 
antibiotic derived from Streptomyces hygroscopicus (Figure 2-3) [33]. Although GDA 
effectively and potently kills cancer cells, it is not a good clinical candidate due to in vivo 
toxicity, instability, and poor solubility [34]. Specifically, GDA contains a reactive quinone 
that produces superoxide radicals causing cell death independent of Hsp90 inhibition [35]. 
Because of this, various groups have put forth a substantial amount of effort and 
resources to modify this compound and eliminate its redox potential. In addition to GDA, 
another natural product, radicicol (RDC), is isolated from the fungus Monosporium 
bonorden (Figure 2-3) [33]. Similar to GDA, RDC competitively binds Hsp90 at the ATP-
binding site. Although GDA and RDC do not have clinical utility, the two natural products 
support the rationale that inhibiting Hsp90 represents a multi-pronged anticancer 
therapeutic approach. This resulted in the design and development of several semi-
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synthetic GDA derivatives. Upon further investigation, it was determined that the C-17 
position of GDA was critical for its mechanism of action and toxic reactivity. As a result, 
17-N-allylamino-17-dimethoxygeldanamycin (17-AAG; tanespimycin), 17-AAGH2 (IPI-
504; retaspimycin), 17-AG (IPI-493), and 17-dimethylamino-17-dimthoxygeldanamycin 
(17-DMAG; alvespimycin) were designed and synthesized (Figure 2-3) [32]. 
By the end of 2003, the first GDA derivative 17-AAG, which adds an allylamine 
substituent to the C-17 position, entered eight Phase I clinical trials. Since then, there 
have been a total of 35 (23% terminated). Of these trials, none progressed past Phase II, 
which decreased enthusiasm for the development of GDA derivatives. Despite being 
reasonably effective against cancer tumor growth in early clinical trials, 17-AAG exhibited 
poor bioavailability. In order to improve this, Infinity Pharmaceuticals designed and 
synthesized the compound 17-AAGH2 (IPI-504; retaspimycin) [36]. This hydroquinone 
hydrochloride salt analog improves the metabolic profile of 17-AAG by eliminating the 
requirement for reduction. Another benefit of this analog was its increased potency of 
Hsp90 inhibition. The development of 17-AAGH2 resulted in 13 clinical Phase I or II trials 
with approximately half terminated or withdrawn. Another semi-synthetic benzoquinone 
ansamycin derivative developed by the same pharmaceutical company is 17-AG (IPI-
493) [37]. At the time, 17-AG was a promising clinical candidate since it is the major 
metabolite of all GDA derivatives and was effective in preclinical xenograft models [38]. 
There have been only two reported 17-AG clinical trials, which ran simultaneously with 
retaspimycin trials, both of which were terminated due to superior effect of retaspimycin. 
Kosan Biosciences designed and developed 17-dimethylamino-17-dimthoxygeldana-
mycin (17-DMAG; alvespimycin) which improved the physiochemical profile of GDA by 
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remaining protonated at physiological pH. 17-DMAG entered six Phase I clinical trials 
(17% terminated) and one Phase II that was terminated. 
Purine-based Inhibitors 
Similar to all ATPases, Hsp90 binds and hydrolyzes ATP, but the chaperone does 
so in a unique way. The molecular chaperone belongs to the Gyrase, Hsp90, Histidine 
kinase, MutL (GHKL) ATPase family, all of which share a special β-α-β fold containing 
four motifs I-IV. A pair of motifs within the fold interact with a different moiety of the ATP 
molecule; motifs I and III interact with the phosphate groups while motifs II and IV with 
the adenine component [39]. Taking advantage of this unique interaction with ATP, 
Chiosis and colleagues at Memorial Sloan Kettering designed the first reported fully 
synthetic small molecule Hsp90 inhibitor, PU-3 (Figure 2-4) [34,40]. After successfully 
arresting growth and differentiation in breast cancer cells, researchers began to enhance 
the purine chemical scaffold in PU-3 and generate derivatives [41]. To-date, there are five 
purine or purine-like compounds that entered clinicals trials, with none progressing past 
Phase II. These inhibitors include: BIIB021, BIIB028, MPC-3100, PU-H71, and 
Debio0932 (Figure 2-4). Two defining characteristics of inhibitors in this class are a 
purine (or purine-like) scaffold with amine and aryl substituents. 
Biogen, Inc. developed BIIB021 and BIIB028, wherein the latter is an optimization 
of the former (Figure 2-4) [34,41-44]. In 2006, two Phase I clinical trials tested BIIB021 
in chronic lymphocytic leukemia and advanced solid tumors. Although BIIB021 eventually 
progressed to two Phase II clinical trials by 2009, major limitations kept it from moving 
through the clinical pipeline. BIIB021 is an effective small molecule inhibitor, but lacks 
potency requiring higher doses to achieve biological effects. Additionally, the chemicals 
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needed to synthesize the molecule on a large scale are toxic and an acceptable 
intravenous formulation is difficult to obtain. Due to these setbacks, Biogen, Inc. designed 
and developed BIIB028. In an effort to improve potency, tolerability, and physical 
properties, the pharmaceutical company used X-ray crystal structure analysis to identify 
the N-7 position on the purine scaffold as an optimal site for modification [42]. After 
developing a series of alkynol analogs, BIIB028 was designed as a prodrug and identified 
as a lead second generation clinical candidate. Although seen through to completion, it 
entered only one trial in 2008. 
MCP-3100 and Debio0932, inhibitors developed by Myrexis and Curtis Pharma 
respectively, entered three trials collectively, and did not demonstrate any clinical promise 
to move beyond Phase II [34]. Conversely, a newer compound, PU-H71, discovered by 
the Chiosis group at Memorial Sloan Kettering, is now listed in five clinical trials as either 
active, recruiting, or terminated (80% active or recruiting) [45]. The Phase I trial that was 
terminated resulted from a drug supply shortage and not a dose limiting toxicity. 
Benzamide Inhibitors 
Serenx Inc. discovered the pyrazole-containg Hsp90 inhibitor, SNX-5422, using an 
ATP-affinity column (Figure 2-5) [34,46,47]. In 2007, the first clinical trial testing SNX-
5422 was posted. To-date there have been 13 trials, with one currently ongoing. This 
compound shows clinical promise due to its bioavailability as a prodrug, but a major 
limitation is its pan-inhibitory activity against all Hsp90 isoforms, with the induction of the 
HSR and resulting dose escalation challenges. 
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Resorcinol Containing Inhibitors 
Using a high-throughput screen, Chueng and colleagues at The Institute for 
Cancer Research in London were the first to identify resorcinol-containing small molecule 
Hsp90 inhibitors [48]. In an effort to optimize this class of molecules, scientists at Vernalis 
and Novartis used structure-based drug design to improve compound solubility by adding 
substituents, which led to the discovery of AUY922 (luminespib) (Figure 2-6) [34,49]. 
Preclinical studies show that this Hsp90 inhibitor is active against tumor growth, 
angiogenesis, and metastasis in a xenograft mouse model [50,51]. In fact, AUY922 
entered 25 clinical trials, both Phase I and II, with two trials currently on-going and one 
recruiting as of February 2019. Similarly, scientists at Synta Pharmaceuticals modified 
the resorcinol scaffold to discover STA-9090 (Figure 2-6) [52]. The Synta group first 
presented this novel inhibitor at the AACR-NCI-EORT International Conference on 
Molecular Targets and Cancer Therapeutics. In 2010, they presented preclinical and 
clinical data at another international cancer conference showing that the second-
generation Hsp90 inhibitor demonstrates higher potency in downregulating oncoproteins 
and pathways than first-generation ansamycin-derived inhibitors. Interestingly, this Hsp90 
inhibitor progressed into Phase III trials and entered nearly 40 trials in total, making it the 
most clinically evaluated Hsp90 inhibitor on record. Around the same time, scientists at 
Astex Therapeutics in the UK discovered another resorcinol containing Hsp90 inhibitor, 
AT13387 (Figure 2-6) [53]. This compound was discovered as part of a fragment-based 
drug design approach by combining NMR and X-ray crystallography. Optimization of the 
compound series led to a resorcinol scaffold that has both high potency and ideal ligand 
efficacy [54]. AT13387 is currently in three active and four recruiting clinical trials. Finally, 
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KW-2478 is an Hsp90 inhibitor discovered by scientists at Kyowa Hakko Kirin in Japan 
(Figure 2-6) [55]. The drug was tested in two clinical trials, one of which was completed 
in 2014 in combination with bortezomib, a proteasome inhibitor, in multiple myeloma. The 
primary objectives of the study were to establish safety of the combination therapy and 
assess overall response rates [56]. 
Miscellaneous 
Other research groups have also designed and developed inhibitors of the 
molecular chaperone but are unique or do not have publicly available structures and 
therefore do not fall into one of the general classes of Hsp90 inhibitors above. These 
compounds include XL888, HSP990, DS2248, and TAS-116 discovered by Exelixis, Inc., 
Novartis, Daiichi Sankyo, Inc., and Taiho Pharmaceutical Co., respectively (Figure 2-7) 
[57-59]. Interestingly, all of these inhibitors manifest the same mechanism of action as 
the aforementioned inhibitors—binding Hsp90’s NTD—except for TAS-116. This drug is 
unique, as it is the first reported compound to enter clinical trials that selectively binds to 
the cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β) [34,60]. Between 2014 and 2017, 
61 patients with advanced solid tumors in Japan and the United Kingdom were enrolled 
in the first-in-human clinical trial testing of TAS-116. The primary objectives of the study 
aimed to identify the maximum tolerated dose, safety, and overall response rates in 
patients with advanced solid tumors taking TAS-116 as a monotherapy intervention [61]. 
In March 2019, results from the study revealed minor adverse events (e.g. Grade 1 or 2) 
related to Hsp90 inhibition and a positive antitumor effect against solid tumors including 
KIT wild-type gastrointestinal stromal tumors (GIST). Additionally, the study identified 
three oral dosing schedules for future trials testing TAS-116. There are two on-going trials 
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in Japan evaluating this cellular compartment selective Hsp90 inhibitor. The trials are 
testing TAS-116 in combination with nivolumab, an immune checkpoint PD-1 inhibitor, in 
metastatic solid tumors or alone in GIST patients (Phase I and Phase II, respectively) 
[62]. 
Since the early 2000s, all Hsp90 inhibitors, except for TAS-116, that have entered 
clinical trials target the NTD of Hsp90. Clinical observations and trial data interpretation 
indicate that this approach carries antitumor efficacy but suffers from toxicities and 
adverse effects including hepatic, cardio, and ocular toxicities, as well as dose-scheduling 
limitations after induction of the HSR. Given the clinical efficacy potential Hsp90 inhibition 
carries, it would be ideal to develop novel Hsp90 inhibitors that can improve upon the 
pharmacodynamic and toxicity profiles of this therapeutic approach. Various efforts have 
been put forth to circumvent these setbacks, such as optimizing the approach to inhibit 
Hsp90’s function. Specifically, certain groups, like Taiho Pharmaceutical Co. and our 
research group, hypothesize that selectively targeting the cytosolic isoforms (Hsp90α and 
Hsp90β) will lead to better clinical outcomes and have the potential to be FDA approved. 
In the following sections we elaborate upon the rational for employing a more selective 
approach to inhibit Hsp90’s function and provide examples to demonstrate recent 
advancements in the field. 
Inhibiting the Hsp90 C-terminal Domain 
Although GDA and RDC bind to the N-terminal ATP binding motif of Hsp90, recent 
studies have demonstrated the existence of a C-terminal ATP binding region as well [63-
65]. Similarly, Hsp90 contains two different binding sites for proteins, allowing the 
chaperone to bind both cochaperones and unfolded client proteins at the C- and N- 
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terminal regions [10,24,63,64]. Unlike the NTD, inhibitors that competitively bind at the 
nucleotide binding site to abrogate ATPase activity, small molecules that target and bind 
the CTD disrupt the association of co-chaperones containing TPR-motifs. This ultimately 
leads to aberrant chaperone function [17]. A hallmark example of a CTD Hsp90 inhibitor 
is novobiocin, a DNA gyrase ATP-binding site inhibitor, and its subsequent analogue KU-
174 (Figure 2-8). Inhibition of the Hsp90 protein folding machinery by novobiocin also 
leads to destabilization of the multiprotein complex (Figure 2-9), which results in 
ubiquitinylation of the client protein, proteasome mediated hydrolysis and in many cases, 
induction of apoptosis in numerous cancer cell types [63,66]. A desirable characteristic of 
novobiocin is the lack of HSR induction, which is a major clinical drawback to all NTD 
Hsp90 inhibitors [67]. It is important to note that although novobiocin and most of its 
derivatives inhibit Hsp90’s function, there has been recent evidence supporting 
paradoxical ATPase activation. Chatterjee et al. report that the novobiocin derivative, KU-
32, binds the CTD which in turn leads to a global change in chaperone structure. This 
structural shift not only promotes ATP binding, but increases ATPase activity [68]. In this 
context, KU-32 is viewed as a positive allosteric modulator of Hsp90 function and could 
be used as a tool to develop AD and PD therapies. In addition to disrupting protein-protein 
interactions (PPIs) between Hsp90 and co-chaperones with distinct chemical scaffolds, 
such as novobiocin, Rahimi et al. demonstrated blockade of heterocomplex chaperone 
PPIs with a unique small molecule, LB76 [69]. This molecule was designed de novo using 
an amino acid sequence specific to the MEEVD region of the TPR-motif on the CTD. 
Prior to studies by Prodromou and coworkers in 2006, no crystal structure of full-
length Hsp90 protein had been solved [23]. Two binding sites for ligands are suggested 
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by this structure. One is located in the NTD and the other appears proximal to the 
dimerization domain. Clearly, a co-crystal structure of Hsp90 bound to novobiocin would 
be helpful towards further elucidation of the CTD binding site. However, the affinity of 
novobiocin for the CTD is too low for co-crystallization studies [63,67,70]. 
  In 2004, Cox and coworkers demonstrated that the Hsp90-dependent transcription 
factor, aryl hydrocarbon receptor (AhR), was preferentially sensitive to the effects of NTD 
inhibitors and p23 concentration, whereas inhibition of the CTD with novobiocin remained 
unaffected by p23 concentration. Through subsequent studies, they determined that GDA 
and RDC were unable to overcome the effects of overexpressed p23, because NTD 
inhibitors competed for the same region. In contrast, they found that inhibition of the CTD 
with novobiocin was independent of p23 concentration [71]. 
Our group has since demonstrated these inhibitors have potent in vitro and in vivo 
efficacy in human xenograft tumors and do not initiate the HSR with Hsp70 upregulation 
[72-77]. These preclinical proof of concept studies provide supportive evidence that 
alternatives to NTD Hsp90 inhibition may have the ability to overcome the limitations of 
prior inhibitors in clinical trials and should be further validated [72-77]. 
Isoform-Selective Inhibition 
As aforementioned, the mammalian Hsp90 family of molecular chaperones is 
comprised of three subfamilies, with a total of four distinct isoforms – Hsp90α, Hsp90β, 
Grp94, and TRAP1 (Table 2-1). To better understand the rationale for selective inhibition 
of Hsp90, the following subsection will provide information on the biological relevance of 
each isoform. 
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Biological Functions of Hsp90 Isoforms 
Hsp90α and Hsp90β 
As the two most abundant isoforms, Hsp90α and Hsp90β are predominantly found 
in the cytoplasm of mammalian cells. Despite this, there have also been reports of nuclear 
localization, albeit minor amounts [78]. A major distinction between the two isoforms is 
their expression profile. Hsp90α is the induced isoform, whereas Hsp90β is constitutively 
expressed. The major functions of the cytoplasmic isoforms are to aid in protein folding 
and prevent protein aggregation; in line with that of the Hsp90 family. Reported client 
proteins of Hsp90α and Hsp90β are involved in several cellular processes such as 
signaling pathways, survival, cell cycle, energy metabolism, and epigenetics – to name a 
few – making cytoplasmic Hsp90 isoforms indirectly involved in the regulation of these 
processes [79]. Moreover, several of these processes, if not all, are recognized as a 
hallmark of cancer [80]. Lastly, an extracellular form of Hsp90α (eHsp90), which is 
secreted from the cell, is implicated in invasion and migration or wound healing [29,81]. 
Since eHsp90 has been reported to play a role in wound healing, this extracellular form 
of the chaperone could be an alternative target for novel anticancer therapeutics. 
Grp94 
Unlike its cytoplasmic family members, Grp94, also known as endoplasmin, is 
found exclusively in the endoplasmic reticulum (ER) [82]. Here, it functions to orchestrate 
protein quality control on a small subset of proteins either secreted and/or membrane 
proteins [83]. Proteins that are misfolded in the ER are typically triaged to the Grp94 
molecular chaperone machinery for proper refolding. On the contrary, if an ER protein is 
not properly folded it is translocated to the cytoplasm, where it can be marked for 
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degradation. In addition to serving as a chaperone for a large number of ER-specific 
proteins, Grp94 also plays an important role as a Ca2+ binding protein [84,85]. 
TRAP1 
The last Hsp90 isoform, TRAP1 or tumor necrosis factor (TNF) receptor associated 
protein 1, is located in the mitochondria and was initially reported as the chaperone for 
TNF receptor 1, hence its name [86,87]. In recent years, researchers have shown 
TRAP1’s function in the mitochondria to extend much further than proteostasis, and in 
fact, play a major role in mitochondrial homeostasis. For example, TRAP1 has been 
shown to be involved in the regulation of the organelle’s redox state [88]. Additionally, 
TRAP1’s involvement in diseases, such as cancer, has been speculated to result in the 
disruption of energy metabolism, which ties into the fact that Hsp90 is the chaperone for 
two proteins involved in the citric acid cycle [79,89-91]. Additionally, this alteration or 
“metabolic rewiring” has been suggested to have an intimate interplay with epigenetics 
and Condelli et al. provide thorough perspectives on the matter [79]. In fact, Dr. Oliver 
Kramer, from Johannes Gutenberg University, presented work at the 9th ICHCM that 
detailed the use of Hsp90 inhibitors in combination with histone deacetylase 6 (HDAC6), 
an epigenetic “eraser” of acetyl groups from histones, in acute myeloid leukemia [29]. 
While the exact mechanism(s) in which Hsp90 is involved in altered metabolism and 
epigenetics has yet to be elucidated, we further emphasize here, the critical and indirect 
role the chaperone has in various cellular processes. 
Rationale for Selective Inhibition 
Now with a fundamental understanding of all four isoforms biological functions, it 
is apparent there is some overlap between them, but more importantly, it underscores the 
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necessity to move away from “pan-inhibitors” and develop isoform-selective compounds. 
Moreover, this highlights an opportunity to target a specific isoform whose function is 
much more crucial in a given a disease state than another isoform. As previously 
mentioned, Hsp90 is responsible for the conformational maturation of a myriad of client 
proteins associated with all ten hallmarks of cancer, various neurodegenerative diseases, 
infections, and other disease states. Many of these client proteins depend upon a single 
Hsp90 isoform for their maturation, activation, and/or trafficking. Hsp90 has been shown 
to play an important role in tumorigenesis through the folding/activation of signaling 
kinases, steroid hormone receptors, tumor suppressors, and more [2]. For example, the 
mitogen activated protein kinase (MAPK) pathway kinase, B-Raf, is not only mutated in 
60% of melanoma patients, but also is a client protein of the Hsp90 heterochaperone 
complex, suggesting that chaperone function helps to facilitate stabilization of this kinase 
which ultimately contributes in the mutated and overexpressed state to oncogenesis [92]. 
As mentioned previously, Hsp90 plays a critical role in neurodegenerative disorders such 
as AD and PD. In AD, Hsp90 exacerbates the formation of neurofibrillary tangles through 
the promotion of tau hyperphosphorylation; in PD, pharmacological induction of the 
chaperone machinery has been shown to prevent the self-assembly of Aβ aggregates 
[93,94]. Recall that Hsp90α and Hsp90β are two of the four Hsp90 isoforms that primarily 
reside in the cytoplasm to fold nascent polypeptides. Grp-94, the Hsp90 isoform localized 
to the endoplasmic reticulum, has a much smaller client list and includes Toll-like 
Receptors (TLRs), integrins, insulin-like growth factors, and has been shown to play a 
role in tumor immunogenicity [95,96]. TRAP1 is the mitochondrial isoform of Hsp90 that 
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plays a role in the transition to aerobic glycolysis, accumulation of reactive oxygen 
species, and the maintenance of protein homeostasis [97]. 
While the mechanism of Hsp90 has been well explored and a variety of inhibitors 
have been developed, most inhibitors manifest pan-inhibitory activity against all four 
Hsp90 isoforms. Not only do pan-inhibitors serve little utility for the elucidation of the 
biological roles played by each Hsp90 isoform, but most have been removed from clinical 
evaluation due to toxicity concerns including hepatic, cardio, and/or ocular toxicities, as 
well as induction of the HSR [35,98,99]. Recent work has demonstrated that the human 
Ether a-go-go Related Gene (hERG) product, which is responsible for repolarization of 
the cardiac action potential, is dependent upon Hsp90α for its maturation and trafficking 
[98]. Furthermore, pan-inhibition of Hsp90 also induces the pro-survival HSR by activating 
HSF1, which then induces the transcription of Hsp27, Hsp70, Hsp90, and other heat 
shock proteins [100]. The upregulation of Hsp90 requires an escalation in drug-dosing as 
well as significant scheduling difficulties. As a result of these observations, it was 
proposed that isoform-selective inhibition of Hsp90 may provide a viable way to mitigate 
the detriments and complications observed in clinical trials with pan-inhibition of all four 
Hsp90 isoforms. Furthermore, isoform-selective inhibitors provide a mechanism to 
elucidate the biological role played by each isoform in various diseases. Given the 
aforementioned dependence of clients upon individual isoforms, isoform-selective 
inhibitors could be used to target specific disease states in which one isoform may play a 
presiding role. 
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GRP94-Selective Inhibitors 
Differences between the N-terminal ATP-binding pockets of Grp94 and Hsp90 
were first elucidated using N-ethylcarboxamidoadenosine (NECA) as a competitive 
inhibitor in an adenosine-based ligand binding assay (Figure 2-10) [101]. Despite 
structural similarities between Grp94 and Hsp90, and the large abundance of Hsp90 as 
compared to Grp94 within cells, NECA was able to selectively bind suggesting that Grp94 
could be selectively targeted [101]. Grp94 was the first Hsp90 isoform for which isoform-
selective inhibitors were pursued. 
One approach used to develop pan-Hsp90 inhibitors combined the structural 
features of GDA and RDC, two well established natural product Hsp90 inhibitors, to form 
chimeric molecules. These chimeric molecules retained the key binding features of each 
natural product, but reduced the structural complexity associated with their preparation. 
The first three chimeric inhibitors produced were radanamycin, radamide, and radester. 
All three of these chimeric inhibitors manifested anti-proliferative activity against MCF-7 
human breast cancer cells and induced the degradation of Hsp90-dependent client 
proteins, HER2 and Raf (Figure 2-10) [102-104]. Co-crystallization of radamide bound to 
both Grp94 and Hsp90 revealed a unique 5’-extension pocket that was present only in 
Grp94, which was produced by a five amino acid insertion into the primary sequence that 
led to formation of this unique pocket. Otherwise, Grp94 and other Hsp90 isoforms share 
~85% identity in this region [105]. The co-crystal structures demonstrated that selectivity 
was conferred through isomerization of the radamide bond, resulting in formation of the 
cis-amide, which highlighted the need to incorporate a cis-amide bioisostere into the 
structure of radamide to develop Grp94-selective inhibitors [105]. 
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BnIm was produced by replacement of the cis-amide with a bioisoteric imidazole 
ring that mimicked the amide heteroatoms, while projecting the two appendages into a 
cis-orientation (Figure 2-10) [106]. A functional assay was developed to evaluate the 
effect of BnIm on TLR trafficking to the cell surface, which is Grp94-dependent [106,107] 
No cytotoxic effects were observed with BnIm and no degradation of Hsp90α/Hsp90β 
client proteins were observed at concentrations that affected TLR trafficking, which 
demonstrated a considerable selectivity of BnIm for Grp94 versus the cytosolic isoforms 
[106]. Second generation Grp94-selective inhibitors established structure-activity 
relationships for the BnIm scaffold and replaced the imidazole ring with other heterocycles 
to improve affinity, while modifying the benzyl appendage to improve selectivity and 
affinity. It was determined that meta-substitutions were not tolerated, while ortho- and 
para-substitutions improved selectivity [108]. For example, the incorporation of a bromine 
at the para-position demonstrated efficacy in animal studies for the treatment of 
glaucoma, as the accumulation of mutant myocilin levels is Grp94-dependent [109,110]. 
Modification of the imidazole ring via replacement with a phenyl group resulted in a 2-fold 
improvement in affinity versus BnIm and manifested an apparent Kd of 0.63 µM along 
with a 32-fold selectivity for Grp94 versus Hsp90α [108]. Fluorination of this molecule at 
the para-position yielded a compound that manifested an apparent Kd of 0.54 µM along 
with 73-fold selectivity for Grp94 [111]. Resorcinol-based Grp94 inhibitors also took 
advantage of the hydrophobic S2 sub-pocket and ultimately led to compounds that 
manifested low nanomolar affinity, but unfortunately only ~10-fold selectivity for Grp94 
[112]. 
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Because of Grp94’s distinct extension pockets, it accommodated a wide variety of 
purine-based chemical tools that are also selective for this isoform. Chiosis and 
coworkers evaluated an in-house library of ~130 purine analogs in a fluorescence 
polarization assay to identify compounds that bind Grp94 with higher affinity than Hsp90α. 
While many of the compounds displayed a model of the purine-scaffold ligand PU-H54 
bound to both Hsp90 and Grp94, the team demonstrated that the ligand bound to each 
isoform in a different orientation and caused Phe199 to  swing away and expose a major 
hydrophobic cleft in Grp94 that is not available in Hsp90α [113]. While a similar cleft exists 
in Hsp90α, access to Hsp90α’s binding pocket is blocked by Phe138. Compounds were 
found to engage this site and stabilize binding, which conferred Grp94 selectivity [113]. 
PU-WS13, a Grp94-selective purine derivative bound to this pocket and was shown to be 
nontoxic in in vivo assays for target modulation (Figure 2-10). Furthermore, PU-WS13 
disrupted the architecture of the oncoprotein, HER2, at the cell surface. Treatment of 
HER2-overexpressing SKBr3 human breast cancer cells with PU-WS13 led to a 
substantial decrease in HER2 levels, highlighting a new role for Grp94 in disease states 
that are dependent on mutated, modulated, or otherwise modified cell surface receptors. 
These Grp94-selective inhibitors do not induce the HSR, unlike the pan-inhibitors [113]. 
Recently, a Grp94 selective inhibitor, Compound 54, with an IC50 of 2 nM and over 
1000-fold selectivity for Grp94 versus Hsp90α was developed by Xu and coworkers [114]. 
In order to exploit the aforementioned Phe199 shift and to confer Grp94 selectivity, the 
group began with the benzamide moiety and introduced a phenyl ring at the meta-position 
as their lead compound. SAR investigations led to the introduction of an isopropyl 
appendage at the four-position of the benzene ring and a cyclohexanol with an amine 
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linker at the ortho-position of the benzamide scaffold. The compound was shown to 
induce the “ligand-induced” Phe199 shift, validating the mechanism for Grp94 selective 
inhibition. The compound was found to be efficacious in mouse models of ulcerative colitis 
and did not affect Hsp70 expression levels [114]. 
Hsp90α and Hsp90β-Selective Inhibitors 
Cytosolic Hsp90 includes the inducible Hsp90α isoform and constitutively 
expressed Hsp90β, which are the most conserved among the four isoforms. In an attempt 
to avoid the profile exhibited by pan-inhibitors, compounds with selectivity toward the 
cytosolic isoforms of Hsp90 have been pursued with the intent of narrowing the list of 
clients in an effort to reduce on-target side effects that are observed with pan-Hsp90 
inhibitors. Previous studies investigated the efficacy of Hsp90α/β inhibition in Huntington’s 
Disease and demonstrated that selective siRNA knockdown of cytosolic Hsp90 is 
sufficient to decrease mutant Huntington protein (mHtt) levels in HEK cells, which 
illustrates that isoform-selective inhibition leads to the clearance of disease-promoting 
aggregates, without affecting the function of the endoplasmic reticulum and mitochondrial 
chaperones [115]. The cytosolic Hsp90 inhibitor, SNX-0723, demonstrated about 100-
fold selectivity for cytosolic Hsp90 isoforms versus Grp94 and about 300-fold selectivity 
versus TRAP1 (Figure 2-11). However, SNX-0723 manifests a similar affinity for both 
Hsp90α and Hsp90β [115,116]. Ernst and Conor revealed SNX-0723 as a promising lead 
compound for further optimization due to its CNS permeability as well as its selectivity for 
both cytosolic Hsp90 isoforms. Subsequent work by these researchers led to the 
identification of compound 31, a benzolactam-hydroindolone derivative that contains a 
cyclopentyl substituent and exhibits similar pharmacokinetics as SNX-0723, but less 
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cellular toxicity as a result of the 1,000-fold selectivity for cytosolic Hsp90s versus Grp94 
and TRAP1 [117]. Similarly, TAS-116, which was prepared by researchers at Taiho 
Pharmaceuticals, Co. Ltd., was shown to be a cytosolic Hsp90 inhibitor that manifested 
a large selectivity over the non-cytosolic isoforms (Figure 2-11). TAS-116 induced the 
degradation of Hsp90 clients and reduced tumor burden in human xenograft mouse 
models, indicating that inhibition of cytosolic Hsp90 alone has the potential to exhibit 
promising anticancer activity. TAS-116 moved into Phase I clinical trials to define the 
maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary 
antitumor activity of this orally available and selective inhibitor. While ocular disturbances 
are common with Hsp90 inhibitors, those observed in this trial were limited to grade 1 and 
a partial response was observed in patients with various tumors and mutation statuses 
[61]. While compounds have been prepared to manifest selectivity for both cytosolic 
Hsp90 isoforms as compared to Grp94 and TRAP1, the generation of compounds that 
are selective for either Hsp90α or Hsp90β proved to be a more challenging task. Hsp90α 
and Hsp90β share approximately 95% identity within the N-terminal ATP binding pocket 
and differ by only two amino acids; Hsp90β replaces Hsp90α’s serine and isoleucine 
residues at positions 52 and 91 with alanine and leucine residues, respectively [118]. It 
has been demonstrated that there are three conserved water molecules that play different 
roles in Hsp90α versus Hsp90β due to the replacement of serine with alanine in Hsp90β. 
Based on this observation, this differential hydrogen bonding network was exploited to 
develop the first Hsp90β-selective inhibitors. KUNB31 was the first Hsp90β-selective N-
terminal inhibitor produced and was shown to manifest low micromolar anti-proliferative 
activity, induce the degradation of Hsp90β-dependent clients, and did not induce the pro-
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survival HSR (Figure 2-11) [118]. Studies have also suggested that Grp94-selective 
compounds based on the purine scaffold (PU) also exhibit a 3- to 5-fold selectivity for 
Hsp90α versus Hsp90β [113]. The proposed mechanism for selectivity of the PU 
compounds is based on a conserved N-terminus that is intercepted during quaternary 
transitions between isoforms, suggesting that selectivity must be conferred through a 
region outside the N-terminus. Further work toward the development of Hsp90α- and 
Hsp90β-selective inhibitors is ongoing. 
TRAP1-Selective Inhibition 
Typical pan-inhibitors of Hsp90 have not shown efficient inhibition of TRAP1 in the 
mitochondria due to a lack of permeability and drug accumulation within this organelle. 
The long-standing strategy for TRAP1 inhibition has been to use pan-inhibitors of Hsp90 
that are targeted to the mitochondria. Shepherdin, a cell-permeable peptidomimetic, was 
the first rationally designed molecule to enter the mitochondria and target TRAP1 (Figure 
2-12) [119]. When a highly positively charged moiety was placed at the N-terminus of 
shepherdin, it enabled mitochondrial penetration and induced extensive cell death 
through compromising mitochondrial integrity, which caused swelling, membrane 
depolarization and subsequent release of cytochrome c [120]. Given the peptidomimetic 
nature of shepherdin, it manifested a short half-life and was capable of inducing an 
immunogenic response. Shepherdin also targets cytosolic Hsp90s and induces the 
degradation of several Hsp90 clients [113,121]. Limitations associated with shepherdin 
opened the door for alternative TRAP1 inhibitors that contain a moiety to target pan- 
inhibitors of Hsp90, such as GDA, to the mitochondria. The first inhibitors of this class 
were formed by the inclusion of a triphenylphosphonium (TPP) or cyclic guanidinium 
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moiety onto GDA. These compounds disrupted mitochondrial function, induced cell death 
in cancer cell lines, and affected tumor growth in xenograft mouse models [122]. Other 
compounds soon followed and utilized inhibitors attached to cationic species, including 
SMTIN-P01 (Figure 2-12). SMTIN-P01 replaced the corresponding ammonium group on 
PU-H71 with the mitochondrial permeating TPP moiety [123]. SMTIN-P01 induced 
membrane depolarization and demonstrated cytotoxicity in cancer cells, which implicated 
TRAP1’s role in carcinogenesis. While this method of inhibitor development can traffic 
pan-inhibitors to the mitochondria, it is not truly an isoform-selective process. TRAP1 and 
other isoforms of Hsp90 are highly conserved, but there are still significant differences 
within the ATP-binding regions that make TRAP1-selective inhibitors possible. However, 
compounds may not target TRAP1 with the same affinity observed for the cytosolic 
Hsp90s. A lack of selectivity may also lead to off target effects as compounds may interact 
with cytosolic chaperones. Kang and co-workers sought to minimize the binding to 
cytosolic Hsp90 and to maximize affinity for TRAP1 by the incorporation of guanine 
mimics that contain a piperonyl side chain. Modification of the pyridine ring to provide the 
pyrazolopyrimidine scaffold with a pyridinyl appendage demonstrated stronger inhibitory 
activities against TRAP1 than the corresponding piperonyl-containing side chains, but 
comparable inhibitory activity against cytosolic Hsp90. Further modification of the 
pyridinyl group led to potent inhibitors of TRAP1 (79 nM) as compared to Hsp90 (698 
nM). In fact, DN401, which exhibited ~9-fold selectivity for TRAP1 versus Hsp90, is the 
most selective TRAP1 inhibitor reported to date (Figure 2-12) [124]. 
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Conclusion 
Hsp90 and its isoforms are shown to play a critical role in cancer, 
neurodegenerative disorders, and other disease states, illustrating that its 
pharmacological targeting can have profound implications for the treatment of these 
illnesses. Most attempts at Hsp90 inhibition have not seen success in clinical trials. 
Despite innovative chemistry and targeting these compounds all target the N-terminal 
binding site and therefore are pan-inhibitors of all four Hsp90 isoforms. These inhibitors—
including natural products and their derivatives, purine-based inhibitors, benzamide 
inhibitors and resorcinol containing inhibitors—have time-and-again failed progression in 
clinical trials due to the detrimental toxicities associated with Hsp90 pan-inhibition. In fact, 
over half of the clinical trials with these Hsp90 Inhibitors did not progress past Phase I 
due to the cardiac, hepatic, and ocular toxicities commonly associated with Hsp90 pan-
inhibition, making progress through in-human clinical trials difficult thus far. 
Although Hsp90 pan-inhibitors may not be the key to a combinatorial attack on a 
variety of disease-causing pathways, non-traditional modulation of Hsp90, namely C- 
terminal inhibition or isoform-selective inhibition, remain a viable method to achieve the 
desired anticancer effect without harmful side effects seen with pan-inhibition. Inhibition 
of the cytosolic Hsp90 isoforms maintains the integrity of the endoplasmic reticulum and 
the mitochondria by leaving Grp94 and TRAP1, respectively, unaffected. Inhibition of 
Hsp90β in particular leaves the hERG channel unaffected and avoids induction of the pro-
survival HSR. Grp94 and TRAP1 inhibition allow for the targeting of particular disease 
states in which their isoforms are implicated. Further, preclinical validation and 
advancement of these novel C-terminal and isoform-selective inhibitors will generate 
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exciting new anticancer compounds to move into clinical trials that could overcome the 
challenges of prior Hsp90 inhibitors, providing much needed novel anti-cancer drug 
compounds for patients. 
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Tables 
Table 2-1 Hsp90 family members, gene products, and cellular locations 
There are three Hsp90 subfamilies and each located in different cellular compartments. The majority of isoforms are in 
the cytoplasm and include Hsp90 and Hsp90. The endoplasmic reticulum and mitochondria isoforms are Grp94 and 
TRAP1, respectively. 
 
Subfamily Gene(s) Protein Isoform(s) Cellular Location 
HSP90A 
HSP90AA1,  
HSP90AA2 
Hsp901,  
Hsp902 
Cytoplasm 
HSP90B1 Hsp90 Cytoplasm 
HSP90B HSP90B1 Grp94 Endoplasmic reticulum 
TRAP TRAP1 TRAP1 Mitochondria 
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Figures 
Figure 2-1 Structure of Hsp90 
A schematic of Hsp90’s homodimer structure. Each monomer has a N-terminal (NTD; grey), middle (MD; blue), and 
C-terminal (CTD; orange) domains. The NTD and MD are connected by a charged linker region (black line). 
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Figure 2-2 Clinical trial overview of Hsp90 inhibitors 
18 Hsp90 inhibitors have entered the clinical pipeline totaling over 170 trials. A) There are currently 7 inhibitors in active 
or recruiting trials (green or orange, respectively). B) The majority of inhibitors have not progressed past Phase I. Note: 
active trials testing TAS-116 are in Japan.  
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Figure 2-3 Hsp90 inhibitors derived from natural products   
A) Geldanamycin is a benzoquinone ansamycin antibiotic. Three of its derivatives (tanespimycin, IPI-493, and 
alvespimycin) make substitutions to the C-17 position. B) In addition to a C-17 substitution, retaspimycin is the reduced 
derivative of GDA. C) Radicicol is an antifungal natural product. 
 
  
O
O
R
N
H
O
O
OH
O
O
O
NH2
HO
OH
Cl
O
O
O
H
H
Radicicol (RDC)
Geldanamycin (GDA) R = OMe
Tanespimycin (17-AAG) R = NHCH2CHCH2 
IPI-493 (17-AG) R = NH2 
Alvespimycin (17-DMAG) R = NHCH2CH2N(Me)2
A)
O
B) OH
OH
H
N
N
H
O
O
OH
O
O
O
NH2
Retaspimycin (17-AAGH2)
C)
  87 
 
 
Figure 2-4 Purine-based Hsp90 inhibitors 
A) PU-3 was the first fully synthetic Hsp90 inhibitor and first of the purine-based class. B) BIIB021 and BIIB028 modify 
the N-7 and N-9 positions of the purine base. C-E) PU-H71, MPC-3100, Debio0932 each add a unique 1,3- benzodioxole 
moiety to the N-8 position via a thioether bond and a variable substituent to the N-9 position. 
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Figure 2-5 Benzamide Hsp90 inhibitor 
SNX-5422 is a pyrazole-containing inhibitor and the only of its class.  
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Figure 2-6 Resorcinol-containing Hsp90 inhibitors 
All inhibitors in this class contain a resorcinol moiety. A-C) Luminespib, ganetespib, and onalespib add two 
substituents to the resorcinol ring at ortho-positions to the hydroxyl groups; one is an isopropanol moiety and 
the other is unique to each compound. D) KW-2478 adds three substituents to the resorcinol moiety – two ortho 
and one meta to the hydroxyl groups. 
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Figure 2-7 Miscellaneous Hsp90 inhibitors 
HSP990 and XL888 do not fall into any of the chemical structure categories listed previously, but still target the N-
terminal ATP-binding site. TAS-116 is a Hsp90/ isoform-selective inhibitor. 
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Figure 2-8 Structures of C-terminal Hsp90 inhibitors 
The aminocoumarin antibiotic A) novobiocin derived from Steptomyces niveus and its analogue B) KU174. 
Compounds in this class share three common moieties: benzoic acid derivative, coumarin residue, and sugar 
novobiose. 
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Figure 2-9 Hsp90 C-terminal inhibition 
From upper left: Hsp90 chaperone and HSF1 transcription factor interaction is destabilized by C- terminal Hsp90 
inhibitor binding. Once HSF1 is phosphorylated it associates with other phosphorylated HSF1 proteins and binds to 
DNA at its transcription element, HSE. After a tightly regulated process with several steps, this leads to ubiquitinylation 
of client proteins. 
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Figure 2-10 Structures representing various Grp94-selective inhibitors 
Radanamycin, radamide, and radester are natural product derived. BnIm maintains the resorcinol moiety but introduces 
an imidazole ring. The PU compounds represent the purine class, and 54 is a novel inhibitor of the benzamide class. 
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Figure 2-11 Hsp90 isoform-selective inhibitors 
TAS-116 and KUNB31, the first N-terminal, Hsp90α/β and Hsp90β isoform-selective inhibitors, respectively. 
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Figure 2-12 TRAP1-selective inhibitors.  
Shepherdin is the minimal nine amino acid sequence of survivin named for its binding to the “shepherding” protein 
Hsp90. SMTIN-PO1 represents compounds conjugated to mitochondrial targeting moieties, and DN401 is the most 
potent and selective TRAP1 inhibitor reported. 
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Abbreviations 
17-AAG 17-N-allylamino-17-dimethoxygeldanamycin 
17-AAGH2 17-allylaminodimethoxygeldanamycin hydroquinone 
17-DMAG 17-dimethylamino-17-dimthoxygeldanamycin 
A   -amyloid 
AD   Alzheimer’s disease 
AhR  aryl hydrocarbon receptor  
CTD   C-terminal domain 
DLT   dose-limiting toxicities  
eHsp90 extracellular Hsp90 
ER  endoplasmic reticulum 
FDA  Food and Drug Administration  
GDA  geldanamycin 
GHKL  gyrase, Hsp90, histidine kinase, MutL 
GIST  gastrointestinal stromal tumors 
HDAC6 histone deacetylase 6 
hERG  human Ether a-go-go Related Gene 
HSE  heat shock element 
HSF1  heat shock factor 1 
Hsp  heat shock protein 
Hsp90  90kDa heat shock protein 
HSR  heat shock response 
ICHCM International Conference on the Hsp90 Chaperone Machine 
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MAPK  mitogen activated protein kinase  
MD   middle domain 
mHtt  mutated Huntington protein  
NECA  N-ethylcarboxamidoadenosine  
NTD   N-terminal domain 
PD   Parkinson’s disease 
PPI  protein-protein interactions  
PU  purine scaffold 
RDC   radicicol  
TNF  tumor necrosis factor  
TPP  triphenylphosphonium 
TPR   tetratricopeptide repeat  
TRAP1 tumor necrosis factor receptor associated protein 1 
TRL  Toll-like Receptor 
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Chapter 3   
A Novel C-Terminal Hsp90 Inhibitor KU758 Synergizes Efficacy in Combination 
with BRAF or MEK Inhibitors and Targets Drug-Resistant Pathways in BRAF-
Mutant Melanomas3 
 
Abstract 
Melanoma remains the most aggressive and fatal form of skin cancer, despite 
several FDA-approved targeted chemotherapies and immunotherapies for use in 
advanced disease. Of the 100,350 new patients diagnosed with melanoma in 2020 in the 
U.S., more than half will develop metastatic disease leading to a 5-year survival rate 
<30%, with a majority of these developing drug-resistance within the first year of 
treatment. These statistics underscore the critical need in the field to develop more 
durable therapeutics as well as those that can overcome chemotherapy-induced drug 
resistance from currently approved agents. Fortunately, several of the drug-resistance 
pathways in melanoma including the proteins in those pathways rely in part on Hsp90 
chaperone function. This presents a unique and novel opportunity to simultaneously 
target multiple proteins and drug-resistant pathways in this disease via molecular 
chaperone inhibition. Taken together, we hypothesize that our novel C-terminal Hsp90 
inhibitor, KU758, in combination with current standard of care targeted therapies (e.g. 
vemurafenib and cobimetinib) can both synergize melanoma treatment efficacy in BRAF-
mutant tumors, as well as target and overcome several major resistance pathways in this 
 
3 This chapter in under revision in Melanoma Research and completed in collaboration with Chitra, 
Subramanian, Nina Zhang, Ton Wang, Barbara N. Timmermann, Brian S.J. Blagg, and Mark S. Cohen. 
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disease. Using in vitro proliferation and protein-based Western Blot analyses, our novel 
inhibitor, KU758 potently inhibited melanoma cell proliferation (without induction of the 
heat-shock-response) in vitro and synergized with both BRAF and MEK inhibitors in 
inhibition of cell migration and protein expression from resistance pathways. Overall, our 
work provides early support for further translation of C-terminal Hsp90 inhibitor and MAPK 
pathway inhibitor combinations as a novel therapeutic strategy for BRAF-mutant 
melanomas. 
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Introduction 
Despite Food and Drug Administration (FDA) approval of several targeted 
chemotherapies and immunotherapies, melanoma remains the most aggressive and fatal 
skin cancer. Melanoma incidence is rising yearly with 100,350 new U.S. cases expected 
in 2020 [1]. Of the patients diagnosed, >50% will present with metastatic disease 
decreasing their 5-year survival rate to ~25% [1]. This indicates the critical need for novel, 
more-durable drugs and therapeutic approaches for these patients. Although several 
approved therapies – namely mitogen activated protein kinase (MAPK) pathway and 
immune checkpoint inhibitors – are reasonably effective early-on, the majority of patients 
develop drug resistance within the first year of treatment [2,3].  
A common clinical approach to mitigate resistance utilizes drug combinations that 
simultaneously target multiple pathways. Combination therapy using lower drug doses 
also has the potential to decrease toxicities while improving overall efficacy [4].  In 2014, 
the FDA approved the combination of MAPK pathway inhibitors (MAPKi) targeting BRAF 
(e.g. vemurafenib) and MEK (e.g. cobimetinib) in patients with unresectable advanced 
BRAF-mutant melanomas. A year later, the PD-1 (programmed cell death protein-1) and 
CTLA-4 (cytotoxic T-lymphocyte associated protein-4) monoclonal antibodies were 
approved as first-line immunotherapies in metastatic BRAF-wildtype patients [5]. While 
initial patient responses were promising, emergence of drug-resistance in both 
approaches highlights the need for development of more-durable therapies.  
Targeting the 90-kDa heat shock protein (Hsp90) provides an attractive anticancer 
therapeutic approach as inhibition of chaperone function can target multiple cancer-
promoting kinase pathways simultaneously. As chaperones, Hsps play a crucial role in 
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cellular proteostasis, and more specifically the heat shock response (HSR), by 
maintaining protein folding, stabilization, and activation of a myriad of substrates, referred 
to as clients [6-8]. Hsp clientele are involved in several cellular pathways/processes 
including steroid hormone receptors, protein kinases/phosphatases for signal 
transduction, cell cycle regulation, and gene transcription regulators[9]. Hsp90’s role in 
cancer was elucidated in the 1990s by Whitesell and colleagues after observing that 
oncogenic cell morphology in v-src transformed fibroblasts was reversed with the 
treatment of geldanamycin (GDA), a benzoquinone ansamycin antibiotic [10]. Since then, 
numerous N-terminal Hsp90 inhibitors have been developed and tested in clinical cancer 
trials. This ongoing interest is best explained by Hsp90’s “central node” role in 
chaperoning client proteins involved in all the processes/hallmarks that contribute to and 
maintain the initiation and progression of cancer [11,12]. While no Hsp90 inhibitors 
(Hsp90i) to date are FDA approved as monotherapies, numerous clinical studies show 
their efficacy and anti-cancer potency. Currently 94% of Hsp90i in clinical trials target 
Hsp90’s N-terminal domain and induce the HSR with upregulation of Hsp70. This leads 
to needing higher Hsp90 concentrations to maintain cellular inhibition – a potential 
contributor to dose-limiting toxicities observed in these trials [13]. To address this, we 
developed novel compounds that target the C-terminal as a unique approach for Hsp90 
inhibition that does not stimulate the HSR as robustly. Our group has recently shown that 
C-terminal inhibitors (CT-Hsp90i) are effective in breast cancers, adrenocortical cancers, 
and head and neck squamous cell carcinomas and targeting cancer stem cells (CSC) by 
decreasing CSC markers and downregulating invasion/migration and epithelial-to-
mesenchymal transition both in vitro and in vivo [14-16]. Taken together, we hypothesize 
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that combining a MAPKi (BRAF or MEK) with a new CT-Hsp90i could synergize 
anticancer-effect and provide a novel rational therapeutic strategy for metastatic 
melanoma patients. Such a combination should downregulate major BRAF-resistance 
pathways and dampen the effect(s) of several cancer hallmarks. We evaluate here our 
novel CT-Hsp90i, KU758, alone and in combination with a BRAFi/MEKi for its ability to 
inhibit melanoma cell proliferation, migration, and target melanoma cellular processes 
critical in the maintenance of resistance. 
 
Methods 
Cell Culture and Reagents 
For cell culture, unless otherwise noted, DNA-fingerprint validated human 
melanoma cell lines harboring a BRAFV600E-mutation (UACC-257 and UACC-62) were 
maintained in T-75 flasks (Thermo Fisher Scientific, Waltham, MA) in high glucose and 
L-glutamine Dulbecco’s Modified Eagle’s Medium (Thermo Fisher Scientific, Waltham, 
MA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1% 
penicillin/streptomycin (Thermo Fisher Scientific). Cell lines were incubated at 37°C in 5% 
CO2. The same protocol was followed to culture a human fetal fibroblast (FF) cell line as 
a control. Cells were washed with 1X phosphate buffer solution (PBS), then detached 
using Trypsin-EDTA (Sigma-Aldrich, St. Louis, MO). Drug compounds used included: 
BRAF inhibitor (BRAFi) vemurafenib (Ve) (Selleck Chemicals, Houston, TX), MEK 
inhibitor (MEKi), cobimetinib (Cb) (AdooQ Bioscience, Irvine, CA), novel CT-Hsp90i 
KU758 obtained from Dr. Brian S.J. Blagg (Univ. of Notre Dame, Notre Dame, ID), N-
terminal Hsp90i (NT-Hsp90i) XL888 (AdooQ Bioscience, Irvine, CA), and natural product 
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Hsp90i withalongolide A 4,19,27-triacetate (WGA-TA) obtained from Dr. Barbara 
Timmermann (Kansas Univ., Lawrence, KS). 
Cell Viability Assay 
Cell lines were plated in polystyrene, clear flat-bottom 96-well plates (Thermo 
Fisher Scientific, Waltham, MA) at 1,500 cells/well and adhered overnight. Cells were 
treated in serial concentrations of each inhibitor and left to incubate for 24hrs. To 
determine cell viability, ATP was quantified using a CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, Madison, WI) following the manufacturer’s instructions. The 
luminescence was read using a BioTek Synergy Neo plate reader and Gen5 software 
(BioTek, Winooski, VT). The values collected were imported into GraphPad Prism 
(GraphPad Prism Software, Inc., La Jolla, CA) to obtain dose-response curves and 
calculate the half maximal inhibition concentration (IC50) of each drug in all cell lines. Cell 
viability for FF cells was determined using an MTS assay. Cells were plated in 96-well 
plates at 6,000 cells/well. MTS reagent (Owen’s reagent) was added to each well after 
24hrs treatment period. Absorbance and IC50 values were read and calculated, 
respectively, as stated above. 
Combination Assay 
Cells were plated in 96-well plates, as aforementioned, then treated with a BRAFi 
or MEKi plus a Hsp90i or BRAFi plus MEKi for a total of seven combinations. The drug 
concentrations used were based on the IC50 values of each compound and cells were 
treated with each inhibitor at a range of concentrations (e.g. 1/4x, 1/2x, and 1x IC50) for 
24hrs. The plating and CellTiter-Glo® protocols described above were used for 
combination assays. Following luminescence reading, values were analyzed using the 
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CompuSyn software (Compusyn, Inc., Paramus, NJ), based on the Chou-Talalay 
theorem, to calculate the combination index (CI) of each treatment and determine 
synergistic combinations (e.g. CI<1). Surface maps of combination effects were plotted 
using Combenefit software (Cancer Research UK Cambridge Institute) to illustrate extent 
of biological (viability as percent of control) and synergistic/antagonistic (coloring of map) 
effects. 
Immunoblot Analysis 
Cell lines were cultured to 70% confluency, then treated for 24hrs with a drug alone 
or two in combination – concentrations used: 0.5µM KU758, 0.1µM WGA-TA, 0.3µM 
XL888, 0.125µM Cb, and 50µM Ve. Next, cells were collected, then lysed via suspension 
in a lysis buffer cocktail containing 2µL/mL PR protease inhibitor, 1µL/mL 100M 
phenylmethane sulfonyl fluoride, 2µL/mL 0.5M NaF, and 10µL/mL 100M Na3VO4 
followed by sonication (Qsonica Sonicators, Newtown, CT). After centrifuging (Eppendorf, 
Hamburg, Germany) samples for 20mins at 4°C and 14,000rpm, protein supernatant was 
collected then quantified using a BSA protein standard assay (Thermo Fisher Scientific, 
Waltham, MA) following manufacturer’s instructions. Protein samples were prepped with 
5X loading dye, loaded in equal amounts, and separated using SDS-PAGE. The Precision 
Plus Protein Dual Color Standards (Bio-Rad Laboratories, Hercules, CA) was used as a 
protein ladder. Briefly, SDS-PAGE gels were transferred to nitrocellulose blotting 
membranes (GE Healthcare Life Sciences, Pittsburgh, PA), washed with PBS and PBS-
Tween20, and probed overnight in primary antibodies (Cell Signaling Technologies, Inc., 
Danvers, MA). Next blots were probed with appropriate horseradish peroxidase-linked 
anti-rabbit or anti-mouse secondary antibodies (Cell Signaling Technologies, Inc., 
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Danvers, MA), washed again, and enhanced chemiluminescence horseradish peroxidase 
substrate [SuperSignal West Pico PLUS or Femto (Thermo Fisher Scientific, Waltham, 
MA)] was used to visualize nitrocellulose blots with a digital image using a ChemiDoc 
Imaging System (BioRad, Hercules, CA). -actin was used as a loading control. ImageJ 
software (National Institutes of Health, Bethesda, MD) was used to perform densitometry 
of protein bands. Immunoblot quantification (densitometry) of a given protein band is 
described as a normalized, relative value to the corresponding -actin expression. 
Migration Assays 
Cells were plated in polystyrene, clear flat-bottom 6-well plates at 250,000 
cells/well and adhered overnight. A pipette tip was used to scratch a clear vertical line in 
well. Culture media was removed, and wells were washed with PBS to remove cell debris. 
Images of each well were captured in triplicate using the EVOS FLc microscope and 
camera (Thermo Fisher Scientific, Waltham, MA). Fresh cell culture media was added to 
each well, then treated with each inhibitor alone and in combination with Ve or Cb using 
the determined synergistic drug combination concentrations (see above), for a total of 12 
treatment conditions and one untreated control. Cells incubated at 37°C in 5% CO2 until 
untreated cells migrated and covered previously scratched area (24hrs). Images of each 
well were recaptured in triplicate. For each well, we calculated the percent of the scratch 
zone covered by migrated cells at t=24hrs (higher percentage indicates more cell 
migration).  
 Additionally, Boyden chambers with 8.0µM pore size and PET track-etched 
membranes were used (Falcon, Tewksbury, MA). Cells were seeded at 50,000 
cells/chamber in serum-free DMEM media. Chambers were submerged into polystyrene, 
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clear flat-bottom 24-well plate wells with 20% FBS DMEM media and left to migrate for 
24hrs at 37°C in 5% CO2. After 24hrs, each chamber was removed from the well, then 
fixed with formalin for 15mins and stained with 1% crystal violet, 20% methanol dye for 
30mins. Chambers were washed and images captured using an EVOS FLc microscope 
and camera at 10X magnification. To quantify cell migration, images were used to count 
cells after 24hrs treatment. 
Statistical Analysis 
All in vitro experiments were replicated in triplicate. Significance was determined 
using Student’s t-test (*p < 0.05 and **p < 0.001). Dose-response curves were normalized 
to untreated control for all inhibitors and used to calculate IC50 values with 95% 
confidence intervals in GraphPad Prism, as stated above. Data is presented as mean 
values with standard deviation error bars. SPSS version 25 (IBM, Almont NY) was used 
to verify all statistical calculations. 
 
Results 
KU758 Selectively and Potently Inhibits Growth of BRAF-Mutated Melanocytes 
Before characterizing the combinational effect of KU758+MAPKi on resistance 
pathways and cancer hallmarks, it was pertinent to determine the potency and selectivity 
of KU758 in melanocytes. To evaluate this, we performed a proliferation assay (CellTiter-
Glo®) and compared the IC50 values of 3 different Hsp90i: our novel CT-Hsp90i (KU758), 
the NT-Hsp90i (XL888), and the natural product inhibitor (WGA-TA). All in vitro cell 
viability assays were performed in UACC-257 and UACC-62 human BRAF-mutant 
melanocytes and FF cell line controls. The IC50 of KU758 was consistent across both 
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BRAF-mutant cell lines (360-430 nM) and this was comparable to XL888 and WGA-TA. 
The IC50 of the BRAFi (Ve) and MEKi (Cb) are also listed in Figure 3-1. As a non-
malignant control, fetal fibroblasts (FF cells) were treated with all three Hsp90i. Each 
inhibitor demonstrated a cancer-specific selectivity over normal cells from 10-fold 
(KU758) to 300-fold (XL888) (  
  117 
). 
KU758 Synergizes with MAPK Pathway Inhibitors 
Combination therapy with targeted small molecular inhibitors, such as Ve with Cb, 
is one standard treatment for metastatic melanoma patients with a BRAFV600E/K-mutation 
status. Combination therapy success can be predicted by the extent of synergism, or lack 
thereof, between the two compounds of interest and is quantified by calculating the 
combination index (CI) of a given drug combination. A CI<1, especially <0.5 indicates 
synergistic combinations, while a CI=1 is an additive effect, and a CI>1 indicates an 
antagonistic effect [4,17]. To identify the combination effect of our novel CT-Hsp90i, 
KU758, and a MAPKi (Ve or Cb) on proliferation in BRAF-mutant melanocytes (UACC-
257), we determined the CI of several drug combinations (Table 3-1). Cells were treated 
with Ve or Cb and KU758, XL888, or WGA-TA for seven inhibitor combinations (including 
Ve+Cb) at a range of concentrations based on the IC50 values. The response to 
combination treatment was measured as the percentage of viable cells compared to 
control (Figure 3-2).  KU758 synergized with Ve and Cb, in seven out of nine 
combinations with six having a robust synergy (CI<0.5 for three K758+Ve combinations 
and CI>0.4 for three KU758+Cb combinations typically at 0.5µM KU758; dark blue and 
cyan coloring of the surface plots; Table 3-1). The most synergistic combinations of WGA-
TA+Cb and XL888+Cb were at 0.125µM Cb and 50µM Ve, so these concentrations were 
used for all subsequent studies. Similar to KU758, WGA-TA, synergized with BRAFi and 
MEKi at several drug concentrations, but with only one CI<0.5 (Figure 3-2, Table 3-1). 
Unlike the other Hsp90i, XL888+Cb synergized with relatively mid-to-low CIs, whereas 
CIs in XL888+Ve combinations were predominantly >1 suggesting some antagonism 
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(Figure 3-2, Table 3-1). Since BRAFi and MEKi combinations are already FDA approved 
for use in BRAF-mutant metastatic melanoma patients, combination assays of Ve+Cb 
were performed and CIs were calculated for comparison. As expected, almost all (94%) 
Ve+Cb combinations, between the two cell lines, were synergistic (Figure 3-2, Table 3-1). 
To demonstrate replication of the synergistic combinational effect observed with 
KU758+MAPKi in UACC-257, experiments were repeated in UACC-62 (Error! Reference 
source not found., Error! Reference source not found.) and similar synergistic effects were 
noted. To confirm the inhibitor combinations were effective at promoting cell death, 
protein expression of PARP and its cleaved product were measured (Western Blot) and 
quantified utilizing Image-J software densitometry (compared to ß-actin). All combinations 
synergistically increased the expression of cleaved PARP compared to each treatment of 
each drug alone (p < 0.05) (Figure 3-2). 
Major Resistance Pathway Proteins are Targeted with KU758 Combinations 
After determining the potency/selectivity of KU758 in melanocytes, and its synergy 
in combination with a MAPKi, we next evaluated this combination effect on two major 
BRAFi-resistance signaling pathways in melanoma (MAPK/Erk and PI3K/Akt pathways). 
We hypothesized that since Hsp90 serves as the molecular chaperone for several 
proteins involved in these two resistant pathways, then utilization of Hsp90i+MAPKi will 
lead to subsequent downregulation of these kinase drivers from the resistant pathways. 
To investigate this effect on resistant-pathway protein expression levels, we performed 
immunoblot analysis, then quantified the change in protein expression. Melanocytes 
treated with XL888+Cb or WGA-TA+Cb showed a 2- to 3-fold significant increase in 
expression of Raf1, (p<0.001). However, with XL888+Ve or WGA-TA+Ve combinations, 
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expression of Raf1 was almost entirely ablated. In all instances, there was a significant 
change in protein expression compared to Cb or Ve alone (p<0.05), but not with an 
Hsp90i as a single agent (Figure 3-3). In KU758+Ve and KU758+Cb treated cells, there 
was a significant decrease to Raf1 expression when compared to KU758-only treatment 
(p<0.05) (Figure 3-3). Next, we immunoblotted for p-Erk, a kinase downstream of Raf1. 
In XL888+Cb and XL888+Ve combinations, the phosphorylated kinase was almost 
entirely knocked downed (p<0.01); while it was significantly knocked down with WGA-
TA+Cb, WGA-TA+Ve, and KU758+Cb (p<0.01; Figure 3-3). For p-Akt expression there 
was a 3- and 5-fold increase in cells treated with Cb or WGA-TA alone, respectively. 
Combinations of Hsp90i+MAPKi showed more significant knockdown than any drug alone 
with KU758+Cb having the highest knockdown of expression (95% vs. control), but with 
significant decreases also observed with the WGA-TA and X888 combinations with Ve or 
Cb (all with p<0.01 vs. controls; Figure 3-3). 
Migration is Decreased with Hsp90i+MAPKi Combinations 
Since KU758+Ve and KU758+Cb combinations target key melanoma resistance 
pathways, we next investigated this combination effect on cell migration, since it 
contributes to the potential of a melanoma’s ability to move from one tissue into an 
adjacent one [18]. Extent of cell migration in vitro is also a reasonable surrogate method 
to predict metastatic potential and its associated cellular processes. We hypothesized 
that KU758+MAPKi combinations would effectively decrease melanocyte migration since 
the proteins directly involved with these processes are also Hsp90 clients. 
To determine the effect of Hsp90i alone and in combinations with Ve or Cb on cell 
migration (and indirectly on metastatic potential), we utilized scratch and Boyden chamber 
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assays. For each treatment condition in the scratch assay, scratch distance at t=0hrs and 
t=24hrs was measured, then calculated as percent of cells migrated at 24hrs and 
significance values reflect the quantified change – lower percent migration is desired 
suggesting little to no migration. After 24hrs, untreated/control cells migrated to occupy 
99% of the scratched area representing significant cell migration (p<0.001). Ve and Cb 
single-agent treatments resulted in 83% and 54% cell migration, respectively (p<0.05 vs. 
control), KU758-alone, KU758+Ve, and KU758+Cb resulted in 27%, 20% and 16% cell 
migration, respectively (all p<0.01). Similar decreases in migration were observed with 
XL888 and WGA-TA alone and in combination with a MAPKi (Figure 3-4). These effects 
were then confirmed in our second cell line, UACC-62 (Error! Reference source not 
found.). Immunoblot analysis showed that expression of E-cadherin (an important 
determinant of tumor progression, serving as a suppressor of migration) in KU758 and 
MAPKi single-agent treated cells was low (p<0.05) but its protein expression was 
significantly increased in combination treatments indicating an increase in suppression of 
migration (KU758+Ve and KU758+Cb, p<0.05) (Figure 3-4). Finally, we utilized Boyden 
chambers to quantify the number of cells that migrated from a serum-free media 
environment to a nutrient-rich one with 20% FBS after inhibitor treatment for 24hrs 
(Figure 3-4). All inhibitors alone significantly interfered with the migration of cells 
compared to untreated/control (p<0.001). In combination, only KU758+Ve, KU758+Cb 
and XL888+Ve showed a significant decrease in migration compared to each drug alone 
(p<0.01). 
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The HSR is not Activated in KU758 Treated Cells vs. XL888 
Finally, it was crucial to distinguish the effect of Hsp90i+MAPKi combinations on 
the HSR as 94% of Hsp90i (including XL888) target the N-terminal domain, which many 
experts believe stimulates a HSR with upregulation of pro-survival proteins (Hsp32 and 
Hsp70) requiring subsequent higher Hsp90i doses to overcome and ultimately leading to 
dose-limiting toxicities. As we have shown in other models [14-16], targeting Hsp90’s C-
terminal domain does not upregulate the HSR so we should observe less HSR activation 
with KU758 and KU758+MAPKi combinations. 
To test this, we quantified by Western Blot the change of expression of key Hsps 
– Hsp90, Hp70, Hsp32, and HSF1 in melanoma cells treated with Hsp90i alone or in 
combination with Ve or Cb. In all single-agent and combination treatments, Hsp90 
expression was not significantly altered and remained consistent throughout (Figure 3-5). 
XL888 alone on in combinations significantly increased expression of both Hsp32 (p<0.01 
vs. control) and Hsp70 (16-fold increase vs. control; p<0.01). Compared to XL888, Hsp32 
and Hsp70 expression was significantly decreased in KU758 treated cells (p<0.05). Lastly 
HSF1, a transcription factor required for Hsp32/70 expression, was decreased vs controls 
by KU758(47% decrease), its combinations, WGA-TA+Cb, and XL888+Cb (all p<0.05; 
Figure 3-5). 
 
Discussion 
Since 2011, the standard treatment for metastatic melanoma patients with 
activating BRAF-mutations (V600E/K) has been BRAF+MEK inhibitor combination 
therapy, such as vemurafenib and cobimetinib (Ve+Cb). While this combination has good 
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efficacy initially, the majority of patients acquire drug-resistance within the first year of 
therapy resulting in disease progression [2]. This underscores the major clinical need to 
develop novel therapeutic strategies in melanoma with longer durability. The lack of 
durability of current targeted therapies is due primarily to drug resistance; two of the most 
prevalent resistance mechanisms resulting from BRAF-inhibition include the MAPK/Erk 
pathway and the PI3K/Akt pathway. In drug-resistant melanoma, these resistance 
pathways propagate the hallmarks of cancer and their associated processes. Since 
Hsp90 chaperones proteins involved in all of the hallmarks of cancer, including melanoma 
drug-resistance pathways, inhibiting Hsp90 function would simultaneously down-regulate 
multiple resistance and cancer-propagating pathways, making it an attractive therapeutic 
strategy [19,20]. This therapeutic approach using Hsp90 inhibition has been explored in 
numerous clinical trials targeting the Hsp90 N-terminal ATP binding site. N-terminal 
Hsp90i pan-inhibit all four Hsp90 isoforms leading to a HSR, that in turn upregulates 
several pro-survival processes in the cell including induction of Hsp70 levels. To 
overcome these pro-survival effects, higher doses of Hsp90 inhibitor are required, and as 
noted in clinical trials these NT-Hsp90i trials have been plagued with dose-limiting 
toxicities resulting in a lack of progression to FDA approval. In an attempt to overcome 
this Hsp90i limitation, our research team developed novel Hsp90i that target the C-
terminal region of the molecular chaperone. These have been shown to be equally potent 
to NT-Hsp90i and selective against multiple cancers, but do not induce a significant HSR 
or upregulation of Hsp70 expression, and do not show any significant dose-limiting toxicity 
in vivo [14-16]. 
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In this set of experiments, we demonstrate that our novel CT- Hsp90i, KU758, has 
similarly efficacy and potency to the NT-Hsp90i, XL888, yet is more synergistic in 
combination with Ve or Cb, without activating the HSR and with significantly lower Hsp70 
expression modulation. In our first experiment, we demonstrate that our CT-Hsp90i, 
KU758, had similar efficacy, potency, and melanoma-selectively to an XL888, an NT-
Hsp90i used in several clinical trials. Our 24hrs cell viability assays showed that the IC50 
of KU758 in melanocytes was 0.4µM, which was comparable to the IC50 for XL888 
(0.3µM) and WGA-TA (0.1µM). Additionally, these Hsp90i had 10- to 300-fold selectivity 
for melanocytes compared to the FF control cells. At 72hrs, these IC50 values continued 
to lower (data not shown), indicating increased potency when cells were exposed to each 
drug for a longer period of time.  
After demonstrating that the three Hsp90i had similar potency and melanoma 
selectivity, it was crucial to identify whether they exhibited a synergistic combination effect 
in the presence of a MAPKi, such as vemurafenib or cobimetinib. Optimal combinations 
of our Hsp90i+Ve or Hsp90i+Cb had CI<1 indicating synergism, whereas additive or 
antagonistic combinations had CIs equal to or far greater than 1, respectively. Our 
compound, KU758, not only synergized with Ve and Cb, but with relatively lower CIs 
compared to the other two Hsp90i. It is important to note that all of the combination 
experiments were conducted using the highest concentration (at or near the respective 
compound’s IC50) of Ve, but not Cb. The reason for this is that despite KU758 synergizing 
with Ve at 12.5µM, 25µM, and 50µM, WGA-TA and XL888 only synergized at the highest 
concentration. Therefore, in order to keep as many variables consistent across all Hsp90i 
combinations, 50µM Ve was used for all corresponding treatments. A common 
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observation in all of our Hsp90i+Ve or Hsp90i+Cb was that more synergism was noted in 
Cb-combinations compared to Ve-combinations. One potential explanation for this could 
be that since Cb targets MEK, the downstream effector of Ve’s target, BRAF, there is 
potentially a greater suppressive effect on the MAPK pathway with more distal targeting. 
One of the reasons MEKi were developed was to abrogate compensatory activation of 
the MAPK pathway resulting in the pathway’s downregulation and this is noted especially 
in combination with a BRAFi [2].     
After identifying that KU758 was effective, potent, and synergized with Ve and Cb, 
we took a mechanistic approach to understand and determine the effects of 
KU758+MAPKi combinations on known melanoma resistance pathways. We showed that 
in certain Cb-combinations there was an increase of Raf1 expression, while in Ve-
combinations there was an almost complete decrease. This could in part be explained by 
the fact that Ve innately targets Raf1 and through this there is an overall decrease in its 
expression. Moreover, although Raf1 is a client of Hsp90, WGA-TA and XL888 Cb-
combinations do not synergize to an extent where they result in knockdown of the protein 
product. On the contrary, both KU758 combinations decreased Raf1 perhaps due to a 
more synergistic effect. Further downstream of Raf1, there was varying p-Erk expression 
as the result of Hsp90i combinations. The most notable being in all XL888+Ve and WGA-
TA+Ve combinations with almost complete knock down of p-Erk expression. In 
KU758+Ve, the lack of substantial p-Erk decrease could potentially be the effect of an 
alternative kinase, outside of the MAPK pathway, that activates MEK [2]. Additionally, in 
another drug-resistant melanoma pathway (PI3K/Akt), p-Akt was almost completely 
knocked down in KU758+Cb treated cells. This supports our hypothesis that synergistic 
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combinations of KU758+MAPKi help to mitigate compensatory signaling pathways in 
drug-resistant melanomas. All the Hsp90i tested demonstrated some synergy when 
combined with BRAF/MEK inhibitors and mitigated protein expression levels of key 
regulators from melanoma drug-resistant pathways.  
Next we determined the effects of these inhibitor-combinations on cell migration, 
an important hallmark of cancer. While each Hsp90i showed moderate inhibition of 
melanocyte migration in scratch assays (with KU758 having the most inhibition), this 
effect was more significant when combined with a MAPKi. Evaluating cell migration 
results, each Hsp90i decreased cell migration significantly compared to untreated cells, 
and this inhibition was synergistically enhanced with KU758+MAPKi and XL888+MAPKi 
combinations. Compared to the current standard-of-care melanoma treatment 
combination (Ve+Cb), our Hsp90i+MAPKi combinations had superior effects on cell 
migration. This may be due to the role Hsp90i has in mitigating MAPKi drug-resistant 
pathways simultaneously leading to a more potent therapeutic effect on migration. E-
cadherin (tumor suppressor that plays a role in the transition of stable to invasive tumors) 
expression is lost in melanocytes [21,22]. Down-regulation of the protein subsequently 
leads to a decrease in cell-adhesion molecules, and thus, increased cell motility and 
migration and metastatic spread. In our KU758 combinations, E-cadherin expression was 
significantly increased from controls, again underscoring the effectiveness and synergism 
of the Hsp90i+MAPKi combination on this cancer hallmark of cell migration/metastatic 
potential.  
A distinction between each Hsp90i (and respective combinations with Ve and Cb) 
was its effect on the HSR. This HSR was significantly lower in the CT-Hsp90i KU758 than 
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the NT-Hsp90i XL888. KU758 does not increase the expression of Hsp32, a major pro-
survival Hsp, and rescued protein expression in KU758+Ve or KU758+Cb compared to 
Ve or Cb alone. This highlighted that unlike XL888, XL888+MAPKi and Ve+Cb 
combinations, KU758 does not activate the HSR or significantly increase Hsp32 or Hsp70 
protein expression levels. This finding is significant since the HSR induction observed 
with NT-Hsp90i is thought by many to be a major contributing factor to their dose-limiting 
toxicities and failures in clinical trials. Since KU758 did not induce this HSR and its pro-
survival effects, it may have clinical advantages and lower toxicity than the N-terminal 
inhibitors and warrants future translational studies to better evaluate this potential.   
In conclusion, these studies demonstrate early proof-of-concept that the novel CT-
Hsp90i KU758 is an effective therapy to target BRAF-mutated melanomas with potency 
similar to XL888, an NT-Hsp90i tested in clinical trials. This therapy is potent and selective 
against melanoma cells. It not only synergizes with BRAF and MEK inhibitors to decrease 
melanoma proliferation, but also induces apoptosis through PARP cleavage, inhibits cell 
migration, and mitigates two important drug-resistance pathways; all without inducing the 
HSR, which has potential clinical advantages with lower toxicity concerns than previously 
tested NT-Hsp90i. Also given the advantages of KU758 in mitigating major melanoma 
drug-resistance pathways, this treatment approach could have more durability in the clinic 
than current options and would address an important treatment gap. As such, this data 
supports further translational testing of KU758 in metastatic melanomas in vivo to 
determine its future clinical potential and ideal combinational approach with MAPKi for 
optimal clinical synergy and benefit.  
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Tables 
Table 3-1 Combination effect of Hsp90i+MAPKi.  
The CIs are listed for each inhibitor combination treatment in UACC-257 between (A) Hsp90i+MAPKi, as well as (B) 
Ve+Cb. Synergistic combination boxes are colored according to relative value: CI<0.5 (blue), 0.5<CI<1.0 (green). 
A) 
 
B) 
 
 
 
 
  
  KU758 WGA-TA XL888 
 (µM) 0.125 0.25 0.5 0.025 0.5 0.1 0.075 0.15 0.3 
Ve 
12.5 1.530 0.678 0.837 39.115 6.954 1.380 45.500 5.936 3.132 
25 1.497 0.492 0.566 4.916 1.787 0.868 21.717 3.653 2.465 
50 0.747 0.183 0.088 0.547 0.689 0.479 0.862 0.652 0.938 
Cb 
0.125 1.234 0.762 0.369 1.960 1.404 0.948 0.815 0.310 0.349 
0.25 1.371 0.592 0.371 1.999 1.139 1.132 0.846 0.497 0.512 
0.5 0.927 0.675 0.214 2.058 1.334 1.205 1.028 0.741 0.689 
  Cb 
 (µM) 0.125 0.25 0.5 
Ve 
12.5 0.953 0.887 1.463 
25 0.227 0.324 0.649 
50 0.195 0.343 0.622 
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Figures 
Figure 3-1 Melanocyte viability and IC50 after Hsp90i or MAPKi treatment.  
All inhibitors exhibited efficacy in BRAF-mutant melanocyte (UACC-257 and UACC-62) death after 24hrs treatment 
with a range of potencies (IC50 value). A) The dose-response curves of all three Hsp90i show similar potencies in the 
sub-micromolar range (~0.1-0.4 µM) – ascending IC50: WGA-TA (green) < XL888 (blue) < KU758 (orange).  B) 
Melanocytes were treated with the BRAFi Ve (dark grey) and MEKi Cb (light grey) at several concentrations and the 
dose-response curves indicate higher potency of Cb over Ve. All inhibitor IC50 concentrations are listed below dose-
response curves in micromolar with 95% confidence interval.  
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Figure 3-2 Responses to Hsp90i+MAPKi combinations.  
A) All Hsp90i, (listed left to right) KU758, WGA-TA, and XL888, showed a decrease in UACC-257 cell viability after 
treatment with Ve (top) or Cb (bottom). Each plot shows the percent of cell viability relative to control and illustrates the 
corresponding combination effect (e.g. synergistic, additive, or antagonistic) on a color spectrum. The most synergistic 
combinations were observed in KU758+Ve and KU758+Cb. All six Hsp90i+MAPKi combination abbreviations are 
tabulated. B and C) The expression of cleaved PARP increased in all inhibitor combinations compared to each drug 
alone. 
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Figure 3-3 Hsp90i+MAPKi combination effect on key resistance pathways.  
A) In KU758 treated cells, alone or plus MAPKi, p-Akt expression decreased from untreated (control). Each combination 
decreased p-Akt to a greater extent than each inhibitor alone, especially KU758+Ve (p<0.001). Raf1 expression 
decreased in KU758+Ve, Cb, and KU758+Cb compared to control and each inhibitor alone (p<0.05). Ve, KU758+Ve, 
and Cb combinations increased p-Erk, while KU758+Cb effectively decreased the expression (p<0.05). B) p-Akt 
expression decreased in all Ve- and Cb-combinations, for WGA-TA and XL888, when compared to each inhibitor alone 
(p<0.05). Raf1 expression increased in WGA-TA, WGA-TA+Cb, XL888, and XL888+Cb. p-Erk expression was knocked 
down in WGA-TA+Ve and XL888+Ve combinations (p<0.001). 
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Figure 3-4 Changes to cell migration after exposure to Hsp90i combinations.  
 
A) KU75+MAPKi combinations decreased cell migration compared to inhibitors alone and is represented by fewer cells 
crossing the scratched area (red line). B) The percent of cell migration at 24hrs was calculated with the most significant 
cell migration (>30%) was observed in untreated, Ve, Cb, and WGA-TA treated cells (p<0.05). All other treatments 
mitigated cell migration into the scratched areas. C) The number of migrated cells across the membrane were counted. 
All treatments significantly decreased cell migration compared to untreated (p<0.001). KU758+Ve and KU758+Cb 
decreased cell migration to a greater extent than each inhibitor alone (p<0.05). XL888+Ve and XL888+Cb exhibited 
similar decrease (p<0.05). 
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Figure 3-5 Effect of Hsp90i combinations on the HSR.  
A) There was no significant change to HSF1 or Hsp90 expression in all KU758 and KU758+MAPKi cells. Expression 
of Hsp70 increased in all treatments compared to untreated (control), especially in Ve alone (p<0.05). Hsp32 increased 
in Ve and Cb treatments alone but decreased in KU758+Ve and KU758+Cb (p<0.05). B-E) Hsp70 expression increased 
in WGA-TA+MAPKi and XL888+MAPKi (p<0.05). No change to Hsp90 expression from control after inhibitor treatment. 
Hsp32 expression showed the most drastic increase in XL888 and XL88+MAPKi treated cells (p<0.05). *p<0.01; 
**p<0.001 
 
 
  
  133 
Figure 3-5 continued 
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Abbreviations 
BRAFi  BRAF inhibitor  
Cb  cobimetinib 
CI  combination index 
CT-Hsp90i C-terminal Hsp90i 
FF  fetal fibroblasts 
Hsp90i Hsp90 inhibitor  
IC50  half-maximal inhibition concentration 
MEKi  MEK inhibitor  
NT-Hsp90i N-terminal Hsp90i 
PBS  phosphate buffer solution 
Ve  vemurafenib  
WGA-TA withalongolide A 4,19,27-triacetate 
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Chapter 4 : Summary and Perspectives 
 
Summary and Significance 
For this doctoral dissertation, I researched therapeutic resistance mechanisms in 
BRAF-mutant (BRAF+) melanoma through various preclinical in vitro studies that targeted 
the 90-kDa heat shock protein (Hsp90) molecular chaperone. Specifically, I tested the 
hypothesis that several resistance-promoting processes require Hsp90 function and, 
therefore, could be targeted with an Hsp90 inhibitor (Hsp90i) to simultaneously 
knockdown multiple resistance pathways and oncogenic processes. This body of work is 
significant because I investigated a unique therapeutic combination strategy utilizing a 
novel C-terminal Hsp90i (CT-Hsp90i) plus standard mitogen-activated protein kinase 
(MAPK) pathway inhibitors (MAPKi) targeted therapy in BRAF+ melanoma. Furthermore, 
using a CT-Hsp90i alone or in combination with MAPKi, I was able to target not only the 
key therapeutic resistance pathways in BRAF+ melanoma cell lines but also critical heat 
shock proteins (Hsps) involved in heat shock response (HSR) activation.  
Since 2011, the FDA approved several effective small molecule MAPKi (e.g., 
BRAF/MEK inhibitors [BRAFi/MEKi]) in combination as a first-line treatment for 
unresectable late-stage BRAF+ melanoma. However, the lack of durability of these 
agents still pose a significant clinical limitation to their reliability [1]. Conversely, Hsp90 
inhibition while not an FDA-approved therapy in melanoma, has been a therapeutic 
strategy supported by over 170 clinical trials completed, terminated, or in progress [2]. 
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Moreover, from the 18 Hsp90 inhibitors in the clinical pipeline, nearly all are N-terminal 
Hsp90i (NT-Hsp90i). These inhibitors frequently require dose-escalation to maintain their 
therapeutic efficacy and result in dose-limiting toxicities (DTLs) likely in-part related to 
their activation of the HSR. For these reasons and limited chemotherapy options in 
advanced melanoma patients, there is a need for more durable targeted therapies. 
Optimization of current Hsp90i is a novel and rational approach to create transformative 
scientific and clinical advancements for unresectable late-stage BRAF+ melanoma 
patients. Taken together, this formed the cornerstone of my doctoral research studies. 
First, I presented comprehensive insights on BRAFi/MEKi use and resistance not 
only in melanoma, but several other cancers driven by BRAF-mutations. Next, I discussed 
the current clinical pipeline of Hsp90 inhibitors, especially in oncology. I also outlined the 
rationale for isoform-selective inhibition and introduced Hsp90i development and use in 
other disease states. Finally, I demonstrated robust synergy of a novel CT-Hsp90i, 
KU758, in combination with BRAFi/MEKi (e.g., Ve/Cb) to target two resistance pathways 
effectively (e.g., MAPK/Erk and phosphatidylinositol 3-kinase (PI3K)/Akt), mitigate cell 
migration, and downregulate key Hsps involved in HSR activation (Error! Reference 
source not found.). Here, I also incorporate key published literature in the field to provide 
my final perspectives and recommendations for future work investigating therapeutic 
resistance in BRAF+ melanoma and rationale for advancing Hsp90i through the clinical 
pipeline and into approved therapeutic options for advanced melanoma patients. 
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Future Directions 
While my experiments and research to-date have provided insights into a novel 
preclinical combination strategy in BRAF+ melanoma cell lines using a CT-Hsp90i, there 
remain several unanswered questions. What cellular pathways, outside of MAPK/Erk and 
PI3K/Akt, warrant further investigation in BRAF+ melanoma? Why do CT-Hsp90i affect 
the cell differently than NT-Hsp90i? What pharmacokinetic (PK) and pharmacodynamic 
(PD) attributes of NT-Hsp90i are worth integrating into new Hsp90i? Why do NT-Hsp90i 
lead to several DTLs in patients, but not preclinically in vivo? What biomarkers report 
Hsp90 inhibition or toxicity accurately? Can CT-Hsp90i be used as a pharmacological tool 
to positively modulate the immune response? It is imperative to continue posing these 
questions, among others, and seeking out research-supported answers to contribute to 
the discovery and development of transformative achievements in this field. To be at the 
forefront of advancing the science and translatability of these novel molecules into the 
clinic, a better understanding of the genetic and epigenetic changes of these tumors and 
their key driving or resistant pathways is required. As such, incorporating precision 
medicine approaches and deep sequencing of these tumors will provide additional key 
data and guide in vitro and in vivo combination strategies, including those with immune 
checkpoint inhibitors (e.g., CTLA-4 and PD-1 inhibitors), and better translate more 
successful treatments into the clinic. 
Understanding PK and PD profiles of CT-Hsp90i to optimize therapeutic use 
Regardless of there being nearly 200 clinical trials that test Hsp90i in humans, 
significant strides are needed for these small molecule inhibitors to receive FDA approval 
  140 
[2]. For example, it is recognized by many in the cancer field that Hsp90 is a rationale 
drug target to simultaneously select for multiple signaling pathways [3-5]. Still, toxicity 
profiles of these drug candidates in clinical trial participants remain too high to allow 
progression of these drugs through FDA approval and commercialization [6,7]. In Chapter 
2 of this dissertation, I elaborate more on this point. I reviewed the clinical landscape of 
Hsp90i to give a well-informed perspective on why these compounds have been so 
challenging to achieve FDA approval to-date – most notably, DTLs resulting from the 
inherent PD (e.g., selectivity) of these small molecule inhibitors in the clinical pipeline 
[8,9].  
Currently, 94% of Hsp90i in clinical trials competitively bind at the N-terminal ATP-
binding site of the chaperone and are pan-inhibitors of the heterochaperone complex [2]. 
Additionally, they are not selective for a particular Hsp90 isoform. The non-selective 
nature of NT-Hsp90i may contribute to their toxicity because they inhibit the function of 
all four Hsp90 isoforms (e.g., Hsp90, Hsp90, Grp94, and TRAP1) in essential 
compartments throughout the cell (e.g., cytoplasm, endoplasmic reticulum, and 
mitochondria) [2]. Fortunately, medicinal chemistry and related drug discovery efforts by 
our collaboration with Dr. Brian S.J. Blagg have allowed for the optimization of the Hsp90 
inhibition to selectively target specific isoforms of the molecular chaperone [2,9]. Several 
groups, including ours, are actively improving the PD of Hsp90i to have more isoform-
selectivity, as mentioned above, to mitigate off-target effects. Chapter 2 covered a full 
review of these advancements. Despite the effort for improvement, it will be critical to 
characterize a full PK profile of these compounds, especially for CT-Hsp90i, like KU758, 
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and identify more specific PD biomarkers of Hsp90 inhibition to be able to better track 
toxicity and effectiveness of inhibition clinically.  
In vivo model to examine PK of CT-Hsp90i 
I propose for the future to translate my in vitro studies presented in this work, 
specifically in Chapter 3, into an in vivo mouse model to provide valuable PK/PD insights 
of the CT-Hsp90i KU758. After characterizing the KU758 PK profile, comparing it with the 
PK/PD profiles of an NT-Hsp90i, such as XL888, will be critical to providing essential 
evidence of similarities and discrepancies between the two types of inhibitors. This 
analysis could unveil insights into drug metabolism and how DLTs develop with NT-
Hsp90i compared to CT-Hsp90i or isoform-selective Hsp90i. 
The current understanding is that CT-Hsp90i may have several favorable biological 
effects over NT-Hsp90i. For example, a study from our lab showed promising in vivo 
effects of two CT-Hsp90i, KU711 and KU757, in a head and neck squamous cell 
carcinoma (HNSCC) model compared to an NT-Hsp90i [10]. In this study, using a HNSCC 
buccal orthotopic xenograft model with MDA-1986 cells, our lab demonstrated a decrease 
in tumor volume, prolonged survival, and no significant changes to body weight in CT-
Hsp90i treated mice compared to an NT-Hsp90i (17-N-allylamino-17-demethoxy-
geldanamycin; 17-AAG) or controls. Additionally, histopathology evaluation of the liver, 
kidney, and proliferation marker, Ki67, showed an improved toxicity profile (e.g., less 
toxicity) with CT-Hsp90i treatment compared to untreated controls or 17-AAG. Together, 
this data highlights the beneficial potential CT-Hsp90i, like KU758, over NT-Hsp90i, 
warranting additional translational preclinical investigation and development.  
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In a similar manner, I hypothesize that CT-Hsp90i therapy with a drug like KU758 
in a BRAF+ melanoma orthotopic xenograft mouse model would demonstrate improved 
efficacy in vivo for three key reasons. First, KU758 shares its core chemical structure with 
KU711 and KU757; as all three compounds are novobiocin core analogs [2,10]. For the 
development of these KU-compounds, researchers maintained biologically active 
components of the novobiocin core while altering minimal structural elements, such as 
(thio)urea and side chain components,  to build a library of similar analog compounds and 
optimize their pharmacological effect [10,11]. Second, in vitro biological effects of CT-
Hsp90i, such as decreased cancer cell migration and reduced expression of HSR-related 
proteins, remain reproducible across various cancer models [12,13]. Collectively these in 
vitro findings and others underscore that similar CT-Hsp90i (KU711, 757, 758, etc.) 
effectively target the same biological pathways, and therefore, provides a basis for 
expecting relatively similar phenotypic effects to result in an in vivo model. Lastly, KU758 
decreased tumor size and showed no toxicity in a triple-negative breast cancer orthotopic 
xenograft, which supports in vivo safety in a murine model [12].  
Despite their potential, several gaps still exist in our knowledge of CT-Hsp90i that 
will need to be addressed prior to further clinical development. Future studies must take 
a more in-depth look into the in vivo effects of these inhibitors, beyond just improved 
animal survival and histopathology surrogates of toxicity. For example, in addition to the 
outcomes measured above in KU711 or KU757 treated HNSCC, in Subramanian et al., 
determining clinically relevant PK will be necessary to assess the therapeutic effect, half-
life, and optimal dosing to maximize efficacy and avoid toxicity in a BRAF+ melanoma in 
vivo model. 
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 A comprehensive in vivo study should not only investigate KU758 as a 
monotherapy but also in combination with BRAFi/MEKi, such as vemurafenib (Ve) and 
cobimetinib (Cb), respectively. The results from Chapter 3 showed that KU758 synergizes 
with both Ve and Cb. These combinations had more favorable effects on targeting 
resistance pathways and mitigating cell migration than each compound alone. I would 
expect this same synergy to translate in an in vivo model, and for the combination 
treatments to be advantageous over single-agent intervention. Finally, an in vivo efficacy 
investigation will compare findings of KU758 and KU758+BRAFi/MEKi treated mice to 
XL888 and XL888+BRAFi/MEKi treated animals to demonstrate if the CT-Hsp90i has 
efficacy and toxicity benefits over the NT-Hsp90i. 
Various studies, both preclinical and clinical, tested an NT-Hsp90i (e.g., XL888 or 
AT13387) in combination with BRAFi/MEKi in BRAF+ melanoma (ClinicalTrials.gov 
NCT01657591; NCT02721459)  [14-16]. In preclinical studies, the emergence of 
therapeutic resistance in vitro and in vivo to BRAFi/MEKi was circumvented and delayed 
by introducing an NT-Hsp90i. These data support the rationale for combined targeted 
therapy of Hsp90i+BRAFi/MEKi in BRAF+ melanoma and continuation of Chapter 3 
findings. Interestingly, a Phase I trial reported therapeutic activity of XL888+Ve in BRAF+ 
melanoma treatment-naïve patients with tolerable side-effects and few grade 3/4 toxicities 
(ClinicalTrials.gov NCT01657591). The results of this Phase I trial further support that 
Hsp90 inhibition is a rational anti-cancer therapeutic strategy in melanoma that would be 
enhanced further with a lower toxicity profile. Despite meeting the primary endpoints (e.g., 
identify the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D)), 
the researchers and clinicians of the study recommended further investigation of 
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Hsp90i+BRAFi, especially with a MEKi. The same research group completed a Phase I 
study investigating XL888+Ve+Cb in October 2019, with the final results still to be 
reported (ClinicalTrials.gov NCT02721459). Hsp90i+BRAFi/MEKi remains a rationale 
anti-cancer therapeutic approach with an opportunity to continue the development of CT-
Hsp90i, such as KU758, to decrease off-target effects leading to potential DTLs. In the 
following section, I will propose and discuss ways to address and improve this 
shortcoming in the context of PD.  
Hsp90 inhibition and PD biomarkers 
Since the discovery of geldanamycin as an inhibitor of Hsp90, there were 
significant advancements in the field to circumvent off-target effects, most notably and 
recently being the development of domain-specific and isoform-selective inhibitors. As 
mentioned in the previous section and Chapter 2, pan-inhibitors of the molecular 
chaperone can and often lead to DTLs in the clinic [2]. We understand that DTLs here 
likely resulted from the dose-escalation observed in these trials that was required to 
maintain therapeutic efficacy [17-19]. In the future, it will be critical to achieve durable 
therapeutic levels of an Hsp90i that have low or limited toxicity profiles for it to receive 
FDA approval. Biomarkers are vital tools used to measure not only a drug's biological 
response(s) and activity but also its selectivity [20]. Related to their utility in Hsp90 
inhibition, there is a need to improve current biomarkers to provide more accurate on-
target reporting of this inhibition in vivo and in patients. 
First, it is critical to consider and evaluate the biomarkers used in preclinical 
research and clinical trials. An accepted and relevant biological signature of effective 
Hsp90 inhibition is the increased expression of 70-kDa heat shock protein (Hsp70), an 
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Hsp90 co-chaperone, and decreased expression of select Hsp90 client proteins [21]. A 
practical preclinical example of this biomarker reporting is in Chapter 3, where I 
immunoblotted for Hsp70 and Hsp32 and showed no upregulation of HSR-related 
proteins in KU758-treated (e.g., alone or in combination with BRAFi/MEKi) cells 
compared to cells treated with XL888 or WGA-TA which demonstrated a more robust 
HSR. Additionally, I demonstrated Hsp90 client protein knockdown in key resistance 
pathways (e.g., MAPK/Erk and PI3K/Akt) with both CT- and NT-Hsp90i.  
In clinical trials, the Hsp70 expression profile remains the gold standard for PD 
analysis of Hsp90 inhibition [9]. For example, peripheral blood mononuclear cells 
(PBMCs) are collected from patients and analyzed for changes in Hsp70 expression [22]. 
A caveat of using Hsp70 expression levels as a biomarker of effective Hsp90 inhibition is 
that the increase of Hsp70 expression is also indirectly indicative of Hsp90i toxicity. Hsp70 
has an essential cytoprotective role within cells, especially malignant ones [23]. An 
increase in Hsp70 expression following Hsp90i administration is often accompanied by 
an increased dose of the Hsp90i to reach therapeutic efficacy and contributing to DLTs 
[9]. In this scenario, while an increase in Hsp70 expression does denote effective Hsp90 
inhibition, it also exemplifies its role to protect the cancer cell from the cytotoxic effects of 
that Hsp90 inhibition. Therefore, an increase of Hsp70 expression is often used as a 
surrogate to indicate toxicities. This limitation prompts us with a pivotal opportunity to 
identify more useful and accurate biomarkers that indicate Hsp90 inhibition or predict 
Hsp90i toxicity.  
Before identifying ways to optimize biomarker reporting of Hsp90 inhibition, it is 
crucial to understand why studies thus far have used Hsp70 expression to measure 
  146 
Hsp90i activity. In the cytoplasm, Hsp90 is transiently bound to heat shock factor 1 
(HSF1), a stress-induced regulator of several Hsps, including Hsp90 and Hsp70 [24]. For 
example, Hsp expression levels increase in stressed cells, such as cells in a malignant 
state. The process HSF1 follows is not entirely defined, but broadly, HSF1 dissociates 
from Hsp90, becomes phosphorylated, and aggregates to form HSF1-trimers. The trimer 
translocates to the nucleus where it binds to its genetic regulatory element, heat shock 
element (HSE), resulting in increased expression of several Hsps – collectively referred 
to as HSR activation [25]. Additionally, Hsp90i binding to the molecular chaperone 
disrupts the Hsp90/HSF1 complex, such that HSF1 follows the same process noted 
above, leading to the upregulation of HSR-mediating Hsps. Therefore, an increase of 
Hsp70 expression correlates with effective Hsp90 inhibition [21,24].  
 Since HSF1 dissociation from Hsp90 leads to increased expression of more than 
one Hsp, not just Hsp90, this supports why a more accurate biomarker of molecular 
chaperone inhibition is needed. There are many steps between Hsp90 inhibition and 
increased HSR-activated Hsp expression.  One important aspect of identifying a reliable 
biomarker for Hsp90 inhibition involves acquiring a better understanding of the immediate 
effects of Hsp90i that occur before the onset of the HSR. In Chapter 3, I demonstrated 
similar biological results in KU758 (CT-Hsp90i) and XL888 (NT-Hsp90i) treated cells, but 
with some nuances, especially a decreased induction of HSR in the former. I propose that 
future in vivo studies should take a more in-depth look into these differences, especially 
related to changes in Hsp90 client protein expression that occur early after exposure to 
an Hsp90i. Additionally, analyzing changes to protein-protein interactions could provide 
aid in refining novel Hsp90i biomarkers [26]. It will also be essential to distinguish 
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biomarkers that may be unique for NT-Hsp90i and CT-Hsp90i in the preclinical setting 
that are based mechanistically on differences between the two classes of inhibitors. This 
would be ideal to find as it would allow for better in vivo PK/PD and toxicity analysis.  
Finally, while refining biomarker(s) of Hsp90 inhibition is a logical strategy, 
researchers could use an alternative approach to address increased Hsp70 expression 
as an indicator of toxicity. For example, by disrupting Hsp70's cytoprotective role, it could 
ultimately improve the utility of Hsp90i in humans, while maintaining Hsp70 as a 
biomarker solely for effective Hsp90 inhibition. The blockade of Hsp70 upregulation could 
aid in decreasing the need for dose-escalation of Hsp90i, and theoretically mitigate 
potential DTLs. Many groups have identified Hsp70 inhibition as a strategy to combat its 
cytoprotective role in the cell, but an obstacle that remains is avoiding off-target effects. 
As with any targeted therapeutic development, one important goal is to increase its 
specificity and decrease off-target effects. In a cancer model, Hsp70 blockade would need 
to be specific to malignant cells and not normal cells, as inhibiting Hsp70 in all cells could 
lead to numerous detrimental and toxic effects. Technical methods available to use to 
further investigate this biological effect of blocking Hsp70 expression in the setting of 
Hsp90 inhibition might include using pharmacological intervention (e.g., inhibitors of 
Hsp70), RNA interference (e.g., shRNA, siRNA), or other gene knockout and loss-of-
function studies [27-31].  
Exploiting a genetic approach to improve therapeutic strategies in BRAF+ melanoma 
In Chapter 1 of this dissertation, I discussed the current clinical landscape and 
indication of BRAFi/MEKi use in BRAF+ malignancies. I also elaborated on primary 
(intrinsic) and secondary (acquired) resistance mechanisms many patients experience 
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when taking BRAFi/MEKi. For example, BRAF-wildtype (BRAFWT) melanoma patients are 
intrinsically resistant to BRAFi because the inhibitors have a pharmacophore specific for 
the V600E codon in the mutated form of the protein [1]. Interestingly, it has been reported 
that several BRAFWT patients exhibited transactivation of the MAPK pathway when given 
a BRAFi [32]. Secondary resistance is more challenging to convey concisely since there 
are various modes of acquired resistance. One predominant mechanism of resistance to 
BRAFi is the upregulation of the PI3K/Akt pathway to compensate for the MAPK pathway 
blockade and provide an alternative mode for cell proliferation and growth. The in vitro 
work I presented in Chapter 3 takes a first step towards identifying if CT-Hsp90i can 
effectively overcome this resistance in BRAF+ melanoma. In an in vitro model, I 
demonstrated that KU758 combinations with either a BRAFi or MEKi (e.g., KU758+Ve, 
KU758+Cb) targeted two key BRAFi resistance pathways effectively. Future studies 
should investigate the downstream effect of KU758 combinations on these pathways; 
MAPK/Erk and PI3K/Akt pathways. Additionally, a more clinically relevant in vivo model 
should be created by transplanting patient-derived tumor cells from BRAFi/MEKi-resistant 
melanoma patients into immunodeficient mice (e.g., patient-derived xenograft [PDX] 
model) and then treating these drug-resistant PDX tumors with KU758+Ve or KU758+Cb 
or KU758+Ve+Cb to evaluate the efficacy of inhibitor combinations to mitigate and 
overcome this drug resistance.  
While the in vivo studies mentioned above will need to be completed to better 
understand the translational application of CT-Hsp90i with BRAFi/MEKi, there is also an 
opportunity to take a more pointed approach to target and overcome resistance 
pathways/processes. In the following subsection, I will present recommendations to 
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continue this body of work utilizing precision medicine tools that harness patient-specific 
genomic data and analyses. Specifically, I will discuss genetic analysis of melanoma 
tumors in The Cancer Genome Atlas (TCGA) program and how these data could 
complement, and advance results noted from Chapter 3.  
TCGA perspective and analysis 
 TCGA is a 12-year genomic-based initiative sponsored by the National Cancer 
Institute (NCI) aimed to enhance our understanding of 33 different types of malignancies, 
improve drug discovery, and transform the clinical management of several malignancies 
and diseases [33,34]. The data generated provides insights into the molecular basis of 
cancer, refined tumor subtype classification, and novel therapeutic targets. Additionally, 
the NCI offers various computational tools for researchers to revisit, visualize, and 
analyze the genomic data collected. For melanomas specifically, tumor and biological 
samples were collected and analyzed from 470 patients [35].  
In the context of this dissertation, I was interested in identifying which genes were 
altered most in BRAF+ melanoma patients to refine my mechanistic approach and provide 
a rational genetic approach to continue my work from Chapter 3. It is important to note 
that there are three other genomic classifications (RAS-mutant, NF1-mutant, and triple 
wild-type) of cutaneous melanoma [36]. However, for this body of work and future 
recommendations, I will focus on the BRAF+ signature. To determine gene changes, I 
utilized a next-generation clustered heatmap (NG-CHM) of the TCGA skin cutaneous 
melanoma (TCGA-SKCM) data via The Cancer Proteome Atlas portal [37]. The NG-CHM 
illustrated increases/decreases of messenger RNA (mRNA) expression of 3,520 genes 
in 470 patients, organized into rows and columns, respectively (Error! Reference source 
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not found.). The NG-CHM categorized rows into three groups based on gene variability 
within melanoma and clustered columns into four groups hierarchically. For supplemental 
analysis, I utilized the TCGA – cBioPortal for Cancer Genomics [38].  
The TCGA-SCKM data showed that 52.2% of patients had a mutated form of the 
BRAF kinase, and of these individuals, 84.1% expressed the V600E codon (e.g., 
BRAFV600E). The remaining 15.9% of patients expressed an alternative missense 
mutation or indel at codon 600 [37]. All missense mutations of BRAF caused copy number 
gain or amplification of the gene, which is a significant contributor to BRAFi-resistance 
[39]. See Figure 4-1 for the filter/search criteria of TCGA-SKCM patients.  
Within the NCI Genomic Data Commons portal, it reports that 100% of patients 
received pharmacological therapy, but does not indicate which therapeutic agent(s) or if 
therapeutic resistance occurred [35]. Because of this omission on the portal=--, raw data 
was accessed to determine which late-stage BRAF+ melanoma received BRAFi/MEKi 
treatment. The raw data reported the therapeutic agents received in only 57% of the total 
patient cohort (268/470 patients). Of the patients reported, 14 BRAF+ patients received 
BRAFi/MEKi as a mono- or combination therapy, and therefore were relevant to the 
context of this dissertation (Error! Reference source not found.). Despite being only a 
small percentage of the entire cohort, analysis of these 14 patients will provide beginning 
insights into the BRAF+ melanoma patient population. A caveat to this “snapshot” analysis 
is the need for a much larger patient cohort with this treatment regimen to ensure 
statistical power and translatability of findings noted in the cohort to treatment strategies. 
In the future, these studies could be performed, similar to the analysis here, once all 
therapeutic agent data is populated and integrated into the NCI data portal.  
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Next, I identified changes to mRNA expression in the cohort of 14 BRAF+ patient 
samples to distinguish which pathways and oncogenic processes might contribute to 
melanoma tumor-maintenance, especially therapeutic resistance. To filter through the 
3,520 genes, I utilized the three NG-CHM pre-generated categories, illustrated as red, 
blue, and purple on the left-most side of the heat map next to the dendrogram (Error! 
Reference source not found.). The heat map categorized each as highly variable (1,650 
genes; red), cancer interesting gene (1,520 genes; blue), or a highly variable/cancer 
interesting (346 genes; purple). For all subsequent analysis, the cancer interesting gene 
subset was considered to eliminate variability in mRNA expression data amongst the 14 
patients. I identified 132 cancer interesting genes that were also Hsp90 clients [40]. See 
Figure 4-1 for the filter/search criteria of TCGA-SKCM genes. Of note, several of these 
cancer interesting genes altered in the 14 BRAF+ patients were genes involved in DNA 
damage/repair pathways. The list of these genes includes ATM, BRCA1, BRCA2, 
FANCA, MRE11A, PCNA, and RAD52. Additionally, several genes involved in epigenetic 
mechanisms were also in the list of Hsp90 clients and cancer interesting genes. These 
included DNMT1, EZH2, HDAC6, KAT5, KDM2A, KDM4C, and SMYD3. See Error! 
Reference source not found. for complete list of 132 cancer interesting genes/Hsp90 
clients from the TCGA-SKCM data. Upon further heatmap and quantitative analysis there 
were slight dissimilarities amongst the patient cohort, in terms of mRNA expression 
patterns (Figure 4-2). The quantified data plots the relative mRNA expression of each 
group of genes (e.g., DNA damage/repair or epigenetic modifier) for all 14 patients. The 
median values and interquartile ranges are displayed to account for outliers within the 
data. All values do not show any significant changes from baseline.   
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As mentioned above, the small cohort size of only 14 samples is a significant 
barrier to identifying translatable conclusions however even this small “snapshot” of data 
analysis provides some early insights into this melanoma patient population of interest. 
In order to better evaluate novel therapeutic and resistance-mitigating strategies the use 
of a larger data set, for example an extension of this 14-patient snapshot, will help to 
determine which genes are significantly changed amongst the patient population. The 
current mRNA expression quantification (Figure 4-2) of the DNA damage/repair and 
epigenetic modifier genes does not suggest any specific key players that contribute to 
resistance to BRAFi/MEKi. However, use of a larger dataset in conjunction with an 
additional analytical method, such as fixed gene set enrichment analysis, could identify 
biological pathways, processes, and networks implicated in these resistance mechanisms 
[41]. Not only would this provide added value and refinement to our understanding of 
BRAFi/MEKi resistance in melanoma patients, but also increase the significance of our 
findings. Ultimately, the aim of these genetic analyses would be to identify a key pathway 
or network that is highly dependent on Hsp90 function, therefore rendering it susceptible 
to Hsp90 inhibition by small molecules, like CT-Hsp90i. 
The snapshot analysis above and in Figure 4-2 suggests that DNA damage/repair 
pathways and epigenetic mechanisms are key contributors to patients becoming 
refractory to targeted therapeutic interventions. Given that the altered proteins in these 
pathways are all clients of Hsp90 support the role that an Hsp90i could positively 
coordinate these processes towards mitigating or overcoming therapeutic resistance to 
BRAFi/MEKi. A recent study showed that suppression of two major DNA repair pathways 
enhances MAPK inhibitor efficacy in Ras pathway-driven melanomas [42]. Interestingly, 
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researchers utilized HDAC inhibitors (HDACi) to promote this biological effect. The use 
of HDACi in this context supports the rationale to simultaneously target multiple 
resistance/oncogenic processes. Future work in BRAF+ melanomas should continue to 
look at the biological effects, especially on DNA damage/repair and epigenetic 
mechanisms, of CT-Hsp90i, like KU758, alone and in combination with BRAFi/MEKi or 
possibly an HDACi. Using CT-Hsp90i as a pharmacological tool to identify these changes 
will determine if inhibiting chaperone function coordinately suppresses resistance-
promoting pathways outside of the MAPK/Erk and PI3K/Akt pathways. This finding will be 
key in advancing our knowledge of more diverse underlying mechanisms of resistance to 
ultimately improve therapeutic strategies used to treat BRAF+ melanoma patients. 
Hsp90 inhibition and immunomodulation  
In 2011, the first fully humanized monoclonal antibody (mAb) that targeted an 
immune checkpoint receptor was approved by the FDA for use in melanoma patients. 
This mAb, ipilimumab (trade name Yervoy; Bristol Myers Squibb) binds to and inhibits 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) resulting in activation of the 
immune response [43]. Over the past decade, additional CTLA-4 inhibitors were also FDA 
approved for use in melanoma and various other cancers. Alongside this clinical 
development, another immune checkpoint was utilized to target and activate the immune 
response – programmed cell death protein 1 (PD-1). Anti-PD-1 therapies (e.g., 
humanized mAb inhibitors of PD-1) of this T cell receptor, like pembrolizumab (trade 
name Keytruda; Merck) and nivolumab (Opdivo; Bristol Myers Squibb), were FDA 
approved in 2014 [43].  
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Together these immunotherapies resulted in break-through treatment options for 
melanoma patients, but similar to targeted therapies, like BRAFi/MEKi, therapeutic 
resistance often emerges. Fortunately, efforts have been taken to overcome this 
resistance by combining CTLA-4 and PD-1 inhibitors [44]. Still, on average, approximately 
only 50% of patients will achieve a significant response to therapy and eventually relapse 
within 2 years [45]. This clinical shortcoming highlights the opportunity for novel 
approaches to target resistance-promoting processes. Interestingly, a recent study 
showed the ability to overcome resistance to immunotherapies by targeting metabolism 
processes in melanoma cells [45]. Furthermore, this work by Imbert et al. further supports 
the rationale to target multiple cancer cell processes at once. 
 Hsp90 poses as an ideal anti-cancer target to positively modulate the immune 
response towards anti-cancer effects, especially when combined with immunotherapies. 
Several research groups, including ours, have initiated studies that evaluate the 
therapeutic potential of this combination approach. For example, CTLA-4 and PD-1 
responses were enhanced via upregulation of a few IFIT genes in melanoma cells 
following Hsp90 inhibition [46]. Additionally, in an in vitro breast cancer model, our 
preliminary results showed that CT-Hsp90i and -selective Hsp90i treated cells can 
decrease the secretion of pro-inflammatory cytokines suggesting the ability to overcome 
immunosuppressive effects. Lastly, our lab performed a pilot in vivo study evaluating the 
use of Hsp90i in combination with immunotherapy and showed benefit compared to 
untreated control. Taken together, these beginning insights support future work assessing 
the potential of Hsp90 in combination with immunotherapies to determine its clinical 
feasibility and translation into practice. 
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Overall Conclusions 
 Collectively, this dissertation demonstrates the utility of targeting the molecular 
chaperone, Hsp90, and MAPK-resistant pathways to improve preclinical therapeutic 
strategies for BRAF+ melanoma patients. The work presented here gives a detailed 
perspective of BRAFi/MEKi used in BRAF+ cancers, like melanoma and insights into a 
unique targeted approach to mitigate and/or overcome drug resistance in these 
malignancies. Specifically, I described the current preclinical and clinical pipelines of 
Hsp90i development for the treatment of various cancers, then evaluated original 
research investigating the efficacy of Hsp90i+MAKPi combinations (e.g., KU758+Ve; 
KU758+Cb) in BRAF+ melanoma cell lines. In these data, I showed that KU758 
synergizes with a MAPKi and cooperatively targets resistance pathways/oncogenic 
processes while mitigating HSR induction. Taken together, targeting Hsp90, especially at 
the C-terminus, provides an alternative approach and added value to current melanoma 
therapies. Furthermore, from these findings, in addition to the genetic analysis, it is 
evident that Hsp90 serves as a central node in regulating several vital processes in 
melanoma cells. Future work will build upon this in vitro work to implement a combined 
pharmacologic and genetic approach along with key in vivo studies to distinguish a more 
precise mechanism by which Hsp90i elicit their key biologic effects in drug-resistant 
melanomas.  
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Abbreviations 
17-AAG 17-N-allylamino-17-demethoxy-geldanamycin 
BRAF+ BRAF-mutant 
BRAFi  BRAF inhibitor 
BRAFWT BRAF-wildtype 
Cb  cobimetinib 
CT-Hsp90i C-terminal Hsp90i 
CTLA-4 cytotoxic T lymphocyte-associated antigen 4 
DLT  dose-limiting toxicities 
FDA  Food and Drug Administration 
HNSCC head and neck squamous cell carcinoma 
HSE   heat shock element 
HSF1  heat shock factor 1 
Hsp  heat shock protein 
Hsp70  70-kDa heat shock protein 
Hsp90  90-kDa heat shock protein 
Hsp90i Hsp90 inhibitor 
HSR  heat shock response 
MAPK  mitogen-activated protein kinase 
MEKi  MEK inhibitor 
mAb  monoclonal antibody 
mRNA messenger RNA 
MTD  maximum tolerated dose 
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NCI  National Cancer Institute  
NG-CHM next-generation clustered heatmap 
NT-Hsp90i N-terminal Hsp90i 
PBMC  peripheral blood mononuclear cells 
PD  pharmacodynamic 
PD-1  programmed cell death protein 1 
PDX  patient-derived xenograft 
PI3K  phosphatidylinositol 3-kinase 
PI3K  phosphatidylinositol 3-kinase 
PK  pharmacokinetic 
RP2D  recommended phase 2 dose  
shRNA short hairpin RNA 
siRNA  small interfering RNA 
SKCM  skin cutaneous melanoma 
TCGA  The Cancer Genome Atlas 
Ve  vemurafenib 
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Figures 
Figure 4-1 Selection criteria for patients and genes of interest from TCGA-SKCM heatmap 
The TCGA-SKCM heatmap displayed a total of 470 patients and 3,520 genes. A) Patients with transcriptome profiles 
were sorted based on the presence, or lack thereof, of an activating BRAF mutation (e.g., BRAF+). 245 patients 
presented with BRAF+ and 224 without (BRAFWT). The subset of BRAF+ patients were considered for further analysis. 
B) Genes were selected for based on Hsp90 clients and their variability within the study cohort. Gene variability was 
predetermined by the TCGA heatmap data as cancer interesting (1,520), highly variable (1,650), and a combination of 
both (346). Of the cancer interesting genes, 132 were also Hsp90 clients and used for further evaluation.   
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Figure 4-2 Heatmaps of mRNA expression in 14 BRAF+ Patients 
Data from the TCGA-SKCM heatmap was used to refine analysis. A) Heatmap of mRNA expression for 132 genes 
(e.g., cancer interesting genes and Hsp90 clients) from 14 BRAF+ patients. B) DNA damage/repair pathways and C) 
epigenetic mechanisms genes sorted from larger mRNA heatmap. Both include quantitative analysis of the relative 
mRNA expression data for each set of genes. Values are presented as the median and interquartile ranges to account 
for outliers. Genes are depicted as columns and patients as rows for all heatmaps. Heatmaps are not clustered. 
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Figure A-1 
Dose-response curves of each Hsp90i in FF cells are shown with corresponding 24 hrs IC50 values tabulated in 
micromolar concentrations. 
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Figure A-2 
The combination effect of Hsp90 inhibitor combinations in UACC-62. Ve+Cb combination (FDA approved) is shown for 
comparison. 
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Figure A-3 
The CI values are listed for each inhibitor combination treatment in UACC-62 between (A) Hsp90i and MAPKi, as well 
as (B) Ve+Cb. Synergistic combination boxes are colored according to relative CI value: CI value < 0.5 (blue), 0.5 < CI 
value < 1.0 (green). 
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Figure A-4 
Scratch and Boyden chamber assays in UACC-62. A) KU758 inhibitor combinations decreased cell migration (red lines 
indicate scratched cell-free area). B) quantification of the percent of cell migration at 24 hours after Hsp90i and MAPKi 
combinations. p values are recorded as significance between t = 0 and 24 hrs. C) The number of migrated cells after 
inhibitor single-agent and combination treatments. 
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Figure A-5 
Schematic of MAPK/Erk and PI3K/Akt pathways targeted by CT-Hsp90i. First-line BRAFi/MEKi are listed. 
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Figure A-6 
mRNA expression data of melanoma patients accessed from TCGA-SKCM. Patient data was aggregated into four 
clusters in a hierarchical manner (columns) and genes into one of three categories (rows). Genes were defined as a 
cancer interesting gene, highly variable, or highly variable cancer interesting gene (e.g., left most column next to 
dendrogram illustrated as blue, red, or purple, respectively). Changes to RNA expression levels in melanoma patients 
are colored based on a matrix distribution of red to blue. Legend for all classifications shown at the bottom of the 
heatmap.  
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Table A-1 
14 patients sorted from the NCI TCGA-SKCM heatmap data. Inclusion criteria: BRAF+ signature and data available 
for therapeutic agent(s) used. Data does not include treatment regimen. 
Patient Identifier Therapeutic Agent(s) 
TCGA-GN-A9SD-06A-11R-A40A-07 Vemurafenib 
TCGA-EE-A29T-06A-11R-A18T-07 Vemurafenib 
TCGA-WE-A8ZQ-06A-41R-A37K-07 Vemurafenib; dabrafenib 
TCGA-WE-A8K6-06A-11R-A37K-07 Vemurafenib 
TCGA-DA-A3F5-06A-11R-A20F-07 Vemurafenib 
TCGA-EE-A2GS-06A-12R-A18S-07 Vemurafenib; dabrafenib 
TCGA-WE-A8ZR-06A-11R-A37K-07 Vemurafenib 
TCGA-EE-A29H-06A-12R-A18S-07 Vemurafenib 
TCGA-EE-A29C-06A-21R-A18S-07 Dabrafenib 
TCGA-FR-A728-01A-11R-A32P-07 Dabrafenib; trametinib 
TCGA-ER-A2NG-06A-11R-A18T-07 Vemurafenib 
TCGA-WE-AAA4-06A-12R-A38C-07 Vemurafenib; dabrafenib 
TCGA-GN-A4U7-06A-21R-A32P-07 Vemurafenib 
TCGA-EE-A3AD-06A-11R-A18S-07 BRAF inhibitor 
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Table A-2 
132 genes sorted from the NCI TCGA-SKCM heatmap data. Inclusion criteria: cancer interesting gene and Hsp90 
client. Genes listed in alphabetical order. 
 
Gene Symbol 
ACVR1B DYRK1B LYN RAD52 
AKT1 EIF2AK2 MAFG RAF1 
AKT2 EML4 MAP2K5 REST 
APAF1 EPHA1 MAP3K6 RET 
ARAF ERBB2 MAP4K2 RHOBTB1 
ATF3 ERBB4 MAPK6 ROR2 
ATM ERG MAPK7 RPS6KA1 
AXIN1 EZH2 MATK SIRT1 
BCL2 FANCA MAX SKP2 
BCL6 FBXW7 MDM2 SMYD3 
BID FES MDM4 SRC 
BLM FGFR4 MIF STAT3 
BRAF FGR MLLT3 STAT5A 
BRCA1 FLT3 MRE11A STAT5B 
BRCA2 FNIP1 MTA1 STK38L 
BRMS1 FOXM1 MTOR TBX22 
BTK FYN MUC1 TGFB1 
BTRC GSK3B MYC TGFBR1 
CAMK2B HCK NFIC TIE1 
CAMK2D HDAC6 NOD1 TIMP2 
CAMKK2 HMGA1 NOTCH1 TNFAIP3 
CASP8 HMGCR NTRK1 TP53 
CDC25A IRAK2 PCNA TP53BP2 
CDC25C JAK1 PDGFB TP53INP1 
CDK1 KAT5 PDGFRB TP53RK 
CDK11B KDM3A PIM1 TPR 
CDK4 KDM4C PIM2 TRIM37 
CSNK1A1 KEAP1 PIM3 TSG101 
CUL1 KSR1 PKM2 TYRO3 
CUL4B LATS1 PLK1 VHL 
DAPK1 LATS2 PPARG WT1 
DNMT1 LGALS3BP PRDM1 WWP1 
DYRK1A LIMK1 PRKD1 YES1 
 
